0000355019-20-000054.txt : 20201112 0000355019-20-000054.hdr.sgml : 20201112 20201112172006 ACCESSION NUMBER: 0000355019-20-000054 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201112 DATE AS OF CHANGE: 20201112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FONAR CORP CENTRAL INDEX KEY: 0000355019 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112464137 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-10248 FILM NUMBER: 201308045 BUSINESS ADDRESS: STREET 1: 110 MARCUS DR CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 6316942929 MAIL ADDRESS: STREET 1: 110 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 10-Q 1 fonar_10-q.htm FONAR CORPORATION 10-Q FOR QUARTER ENDED SEPTEMBER 30, 2020

FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the quarterly period ended SEPTEMBER 30, 2020

Commission file number 0-10248

 

  

 

FONAR CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE   11-2464137
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
     
110 Marcus Drive  Melville, New York   11747
Address of principal executive offices)   (Zip Code)

Registrant's telephone number, including area code: (631) 694-2929

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES _X_ NO ___

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for shorter period that the registrant was required to submit such files YES _X_ NO ___

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of accelerated filer, large accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act. (Check one):Large accelerated filer___ Accelerated filer ___ Non-accelerated filer _X_ Smaller reporting company _X_ Emerging growth company ___

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ___ NO _X_

 

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the close of the latest practicable date.

Class   Outstanding at November 6, 2020
Common Stock, par value $.0001     6,447,463  
Class B Common Stock, par value $.0001     146  
Class C Common Stock, par value $.0001     382,513  
Class A Preferred Stock, par value $.0001     313,438  

 

   

 


FONAR CORPORATION AND SUBSIDIARIES

 

INDEX

 

PART I - FINANCIAL INFORMATION   PAGE
       
Item 1. Financial Statements   2  
Condensed Consolidated Balance Sheets - September 30, 2020 (Unaudited) and June 30, 2020   3  
Condensed Consolidated Statements of Income for the Three Months Ended September 30, 2020 and September 30, 2019 (Unaudited)   6  
Condensed Consolidated Statements of Changes in Equity for the Three Months Ended September 30, 2020 and September 30, 2019 (Unaudited)   7  
Condensed Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2020 and September 30, 2019 (Unaudited)   8  
Notes to Condensed Consolidated Financial Statements (Unaudited)   9  
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations   23  
Item 3. Quantitative and Qualitative Disclosures About Market Risk   32  
Item 4. Controls and Procedures   32  
PART II - OTHER INFORMATION   33  
Item 1. Legal Proceedings   33  
Item 1A. Risk Factors   33  
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   35  
Item 3. Defaults Upon Senior Securities   35  
Item 4. Mine Safety Disclosures   35  
Item 5. Other Information   35  
Item 6. Exhibits   35  
Signatures   35  

 

 Page 2 

 

 FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

ASSETS

 

 

   September 30,
2020
  June 30,
2020 *
Current Assets:          

 

Cash and cash equivalents

  $38,763   $36,802 
 Short term investments   32    32 
 Accounts receivable – net   4,191    4,313 
 Accounts receivable - related party   102    6 
 Medical receivable – net   16,293    16,172 
 Management and other fees receivable - net   29,011    27,438 
Management and other fees receivable – related medical practices – net   7,002    6,896 
 Inventories   1,698    1,649 
Costs and estimated earnings in excess of billings on uncompleted contracts   153    153 
 Income tax receivable   —      671 
 Prepaid expenses and other current assets   1,879    1,758 

 

Total Current Assets

   99,124    95,890 
           
 Accounts receivable – long term   2,839    2,730 
 Deferred income tax asset   17,961    18,810 
 Property and equipment – net   20,904    21,364 
 Right-of-use Asset – operating lease   30,489    31,392 
 Right-of-use Asset – financing lease   1,276    1,326 
 Goodwill   3,985    3,985 
 Other intangible assets – net   4,036    4,109 
 Other assets   642    653 

 

 Total Assets

  $181,256   $180,259 

 

*Condensed from audited financial statements.

 

See accompanying notes to condensed consolidated financial statements.

 

 Page 3 

 

 FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

   September 30,
2020
 

June 30, 
2020 *

Current Liabilities:          
Current portion of long-term debt and capital leases  $169   $108 
Accounts payable   1,848    1,965 
Other current liabilities   7,864    8,185 
Unearned revenue on service contracts   4,203    4,105 
Unearned revenue on service contracts – related party   83    —   
Operating lease liability – current portion   3,433    3,370 
Financing lease liability – current portion   136    75 
Customer deposits   912    855 
Total Current Liabilities   18,648    18,663 
           
Long-Term Liabilities:          
Unearned revenue on service contracts   2,761    2,656 
Deferred income tax liability   234    234 
Due to related medical practices   93    93 
Operating lease liability – net of current portion   29,246    30,105 
Financing lease liability – net of current portion   1,201    1,251 
Long-term debt and capital leases, less current portion   859    865 
Other liabilities   161    150 
Total Long-Term Liabilities   34,555    35,354 
Total Liabilities   53,203    54,017 

 

 

 

*Condensed from audited financial statements.

 

See accompanying notes to condensed consolidated financial statements.

 

 Page 4 

 

 FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

LIABILITIES AND STOCKHOLDERS’ EQUITY (Continued)

 

   September 30, 2020 

June 30,

2020

Class A non-voting preferred stock $.0001 par value; 453 shares authorized at September 30, 2020 and June 30, 2020, 313 issued and outstanding at September 30, 2020 and June 30, 2020  $—     $—   
Preferred stock $.001 par value; 567 shares authorized at September 30, 2020 and June 30, 2020, issued and outstanding – none   —      —   
Common Stock $.0001 par value; 8,500 shares authorized at September 30, 2020 and June 30, 2020, 6,459 issued at September 30, 2020 and June 30, 2020, 6,447 outstanding at September 30, 2020 and June 30, 2020   1    1 
Class B Common Stock (10 votes per share) $.0001 par value; 227 shares authorized at September 30, 2020 and June 30, 2020; .146 issued and outstanding at September 30, 2020 and June 30, 2020   —      —   
Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at September 30, 2020 and June 30, 2020, 383 issued and outstanding at September 30, 2020 and June 30, 2020   —      —   
Paid-in capital in excess of par value   183,076    183,076 
Accumulated deficit   (53,707)   (56,215)
Treasury stock, at cost - 12 shares of common stock at September 30, 2020 and June 30, 2020   (675)   (675)
Total Fonar Corporation’s Stockholders’ Equity   128,695    126,187 
Noncontrolling interests   (642)   55 
Total Stockholders' Equity   128,053    126,242 
Total Liabilities and Stockholders' Equity  $181,256   $180,259 

 

*Condensed from audited financial statements.

 

See accompanying notes to condensed consolidated financial statements.

 

 Page 5 

 

 FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

  

FOR THE THREE MONTHS

ENDED SEPTEMBER 30,

REVENUES  2020  2019
Patient fee revenue – net of contractual allowances and discounts  $5,091   $6,045 
Product sales – net   28    192 
Service and repair fees – net   1,925    2,064 
Service and repair fees - related parties – net   28    28 
Management and other fees – net   11,214    11,028 
Management and other fees - related medical practices – net   2,693    2,390 
Total Revenues – Net   20,979    21,747 
COSTS AND EXPENSES          
Costs related to patient fee revenue   2,521    2,863 
Costs related to product sales   132    330 
Costs related to service and repair fees   626    750 
Costs related to service and repair fees - related parties   9    10 
Costs related to management and other fees   5,550    6,005 
Costs related to management and other fees – related medical practices   1,428    1,537 
Research and development   400    472 
Selling, general and administrative   6,163    4,294 
Total Costs and Expenses   16,829    16,261 
Income From Operations   4,150    5,486 
Other Expenses   (140)   —   
Interest Expense   (22)   (21)
Investment Income   112    148 
Income Before Provision for Income Taxes and Noncontrolling Interests   4,100    5,613 
Provision for Income Taxes   (849)   (1,107)
Net Income   3,251    4,506 
Net Income - Noncontrolling Interests   (743)   (1,207)
Net Income – Attributable to FONAR  $2,508   $3,299 
Net Income Available to Common Stockholders  $2,355   $3,097 
Net Income Available to Class A Non-Voting Preferred Stockholders  $114   $151 
Net Income Available to Class C Common Stockholders  $39   $51 
Basic Net Income Per Common Share Available to Common Stockholders  $0.37   $0.48 
Diluted Net Income Per Common Share Available to Common Stockholders  $0.36   $0.47 
Basic and Diluted Income Per Share – Class C Common  $0.10   $0.13 
Weighted Average Basic Shares Outstanding – Common Stockholders   6,447    6,432 
Weighted Average Diluted Shares Outstanding - Common Stockholders   6,575    6,560 
Weighted Average Basic and Diluted Shares Outstanding – Class C Common   383    383 

 

See accompanying notes to condensed consolidated financial statements. 

 Page 6 

 


FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED) 

 

For the Three Months Ending September 30, 2020

   Common Stock  Paid in capital in excess of par value  Accumulated Deficit  Treasury Stock  Non Controlling Interests  Total
Balance - June 30, 2020   1    183,076    (56,215)   (675)   55    126,242 
Issuance of Common Stock   —      —      —      —      —      —   
Net income   —      —      2,508    —      —      2,508 
Distributions - Non controlling   —      —      —      —      (1,440)   (1,440)
Income - Non controlling interests   —      —      —      —      743    743 
Balance - September 30, 2020   1    183,076    (53,707)   (675)   (642)   128,053 
                               

 

 

For the Three Months Ending September 30, 2019

   Common Stock  Paid in capital in excess of par value  Accumulated Deficit  Treasury Stock  Non Controlling Interests  Total
Balance - June 30, 2019   1    181,086    (64,456)   (675)   2,156    118,112 
Issuance of Common Stock   —      1,990    —      —      —      1,990 
Net income   —      —      3,299    —      —      3,299 
Distributions - Non controlling   —      —      —      —      (1,755)   (1,755)
Income - Non controlling interests   —      —      —      —      1,207    1,207 
Balance - September 30, 2019   1    183,076    (61,157)   (675)   1,608    122,854 
                               

 

 Page 7 

 

 FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

    FOR THE THREE MONTHS ENDED SEPTEMBER 30,
    2020  2019
Cash Flows from Operating Activities:           
Net income   $3,251   $4,506 
Adjustments to reconcile net income to net cash provided by operating activities:           
Depreciation and amortization    968    995 
Amortization on right-of-use assets    953    819 
Provision (Recovery) for bad debts    2,227    (239)
Stock issued for costs and expense    —      1,991 
Deferred income tax – net    849    1,004 
Abandoned patents    1    —   
(Increase) decrease in operating assets, net:           
Accounts, medical and management fee receivable(s)    (4,109)   (1,188)
Notes receivable    14    —   
Costs and estimated earnings in excess of billings on uncompleted contracts    —      218 
Inventories    (49)   7 
Income tax receivable    671    —   
Prepaid expenses and other current assets    (125)   233 
Other assets    —      (44)
Increase (decrease) in operating liabilities, net:           
Accounts payable    (117)   (345)
Other current liabilities    (36)   (2,889)
Operating lease liabilities    (796)   (750)
Financing lease liability    12    —   
Customer advances    58    (62)
Other liabilities    10    (13)
Net cash provided by operating activities    3,782    4,243 
Cash Flows from Investing Activities:           
Purchases of property and equipment    (415)   (2,411)
Purchase of short term investment    —      (119)
Cost of patents    (20)   (38)
Net cash used in investing activities    (435)   (2,568)
Cash Flows from Financing Activities:           
Repayment of borrowings and capital lease obligations    (9)   (8)
Proceeds from debt    63    —   
 Distributions to noncontrolling interests    (1,440)   (1,755)
Net cash used in financing activities    (1,386)   (1,763)
 Net Increase (Decrease) in Cash and Cash Equivalents    1,961    (88)
Cash and Cash Equivalents - Beginning of Period    36,802    13,882 
Cash and Cash Equivalents - End of Period   $38,763   $13,794 

 

 See accompanying notes to condensed consolidated financial statements.

 Page 8 

 

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Description of Business

Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name “Health Management Company of America”.

 

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K filed on October 1, 2020 for the fiscal year ended June 30, 2020.

During March 2020 the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and economies which has adversely effected our workforce, liquidity, financial conditions, revenues, profitability and business operations. Generally COVID-19 had caused us to require that much of our workforce work from home and has restricted the ability of our personnel to travel for marketing purposes or to service our customers. The Company experienced a sudden drop in scan volume for a short term period and while the Company is not back to pre-COVID-19 levels, the volume has risen. At the end of fiscal year ending June 30, 2020, the Company was able to enact certain decisions to allow the Company to survive during the global pandemic and from further losses or additional decreases in scan volume. The Company immediately enacted wide scale furloughs, deferment of up to 50% of management salaries, halted variable compensation plans and rent deferrals we negotiated with the majority of all landlords. The Company also received some government stimulus funds from the Paycheck Protection Program (“PPP”) and Medicare advances/stimulus payments. Although we are unable to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19, the Company believes with positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.

 Page 9 

 

 FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Revenues

On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.

 

Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

 Page 10 

 

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Earnings Per Share

 

Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three months ended September 30, 2020 and 2019.

 

Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three months ended September 30, 2020 and 2019, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.

 

Earnings Per Share

 

   Three months ended
September 30, 2020
  Three months ended
September 30, 2019
   Total  Common Stock  Class C Common
Stock
  Total  Common Stock  Class C Common
Stock
Basic                  
Numerator: 
Net income available to common stockholders
  $2,508   $2,355   $39   $3,299   $3,097   $51 
Denominator:                              
Weighted average shares outstanding   6,447    6,447    383    6,432    6,432    383 
Basic income per common share  $0.39   $0.37   $0.10   $0.51   $0.48   $0.13 
Diluted                              
Denominator:
Weighted average shares outstanding
        6,447    383         6,432    383 
Convertible Class C Stock        128    —           128    —   
Total Denominator for diluted earnings per share        6,575    383         6,560    383 
Diluted income per common share       $0.36   $0.10        $0.47   $0.13 

 

 

 Page 11 

 

 FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Recent Accounting Pronouncements

  

In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance will have no material impact on our Consolidated Financial Statements.

 

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of September 30, 2020 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2020 or 2019, and it does not believe that any of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.

 

Reclassifications 

Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net income for any periods presented. 

 Page 12 

 

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

 

(UNAUDITED)

 

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE

Receivables, net is comprised of the following at September 30, 2020, and June 30, 2020:

   September 30, 2020
   Gross Receivable  Allowance for doubtful accounts  Net
Accounts receivable  $4,706   $515   $4,191 
Accounts receivable - related party  $102    —     $102 
Medical receivable  $16,293   $—     $16,293 
Management and other fees receivable  $41,844   $12,833   $29,011 
Management and other fees receivable from related medical practices ("PC’s")  $10,782   $3,780   $7,002 

 

   June 30, 2020
   Gross Receivable  Allowance for doubtful accounts  Net
Accounts receivable  $4,828   $515   $4,313 
Accounts receivable - related party  $6    —     $6 
Notes receivable  $16,172   $—     $16,172 
Medical receivable  $16,172   $—     $16,172 
Management and other fees receivable  $38,501   $11,063   $27,438 
Management and other fees receivable from related medical practices ("PC’s")  $10,218   $3,322   $6,896 

 

 The Company's customers are concentrated in the healthcare industry.

 Page 13 

 


FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Continued)

 

Accounts Receivable

Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided.

 

Long Term Accounts Receivable

 

The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be recognized over the following four years at September 30, 2020 are as follows:

 

2022  $879
2023   827
2024   827
2025   228
Total  $2,761

 

Medical Receivables

Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that will not be collected. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site.

 

Management and Other Fees Receivable

The Company's receivables from the related and non-related professional corporations (PC's) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PC's of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations.

 Page 14 

 

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

 

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)

 

Management and Other Fees Receivable (Continued)

 

Payment of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 66% and 67% of the PCs’ net revenues for the three months ended September 30, 2020 and 2019, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically been within management's expectations.

 

Net revenues from management and other fees charged to the related PCs accounted for approximately 12.8% and 11.0% of the consolidated net revenues for the three months ended September 30, 2020 and 2019, respectively.

 

Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company.

 

The Company’s patient fee revenue, net of contractual allowances and discounts for the three months ended September 30, 2020 and 2019 are summarized in the following table.

 

   

For the Three Months Ended

September 30,

    2020   2019
Commercial Insurance/ Managed Care   $ 946     $ 1,354  
Medicare/Medicaid     197       266  
Workers' Compensation/Personal Injury     3,387       4,294  
Other     561       131  
Patient Fee Revenue, net of contractual allowances and discounts   $ 5,091     $ 6,045  

 

 

 Page 15 

 

 FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

NOTE 4 – OPERATING & FINANCING LEASES

 

During February 2016, FAS issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Lease with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard was effective for us beginning July 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We have also elected the transition package of the practical expedients permitted within the standard which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and indirect costs. The adoption of this guidance had a material impact on the Company’s balance sheet by virtue of including the present value of its future operating lease payments as a liability of $33.3 million and related right-to-use lease assets as of July 1, 2019. At the time of adoption of this guidance we had no significant financing leases.

 

The Company accounts for its various operating leases in accordance with Accounting Standards Codification (‘ASC’) 842 – Lease, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Also included in other current assets is a $202,268 receivable from a landlord for tenant improvements. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company.

 

 Page 16 

 

 FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

NOTE 4 – OPERATING & FINANCING LEASES (Continued)

 

A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of September 30, 2020 is as follows:

 

 

 

Year Ending

September 30,

 

Operating Lease

Payments

  Financing Lease Payments
2021  $5,045   $122 
2022   4,847    244 
2023   4,698    244 
2024   4,485    244 
2025   4,390    244 
Thereafter   18,545    408 
Present value discount   (9,331)   (169)
Total lease liability  $32,679   $1,337 
           

 

NOTE 5 - INVENTORIES

 

Inventories included in the accompanying condensed consolidated balance sheets consist of the following:

 

  

September 30,

2020

 

June 30,

2020

Purchased parts, components and supplies  $1,537   $1,544 
Work-in-process   161    105 
TOTAL INVENTORIES  $1,698   $1,649 

 

 

NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS

 

Information relating to uncompleted contracts is as follows:

 

  

September 30,

2020

 

June 30,

 2020

Costs incurred on uncompleted contracts  $448   $448 
Estimated earnings   309    309 
Subtotal   757    757 
Less: Billings to date   604    604 
Total Costs and estimated earnings in excess of billings on uncompleted contracts  $153   $153 

 

 Page 17 

 

  FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

 

NOTE 7 – OTHER INTANGIBLE ASSETS

 

Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:

  

September 30,

2020

 

June 30,

2020

Capitalized software development costs  $7,005   $7,005 
Patents and copyrights   5,101    5,082 
Non-compete   4,100    4,100 
Customer relationships   3,800    3,800 
Gross Other intangible assets   20,006    19,987 
Less: Accumulated amortization   15,970    15,878 
Other Intangible Assets  $4,036   $4,109 

 

  

Amortization of patents and copyrights for the three months ended September 30, 2020 and 2019 amounted to $45 and $47, respectively.

 

Amortization of non-compete for the three months ended September 30, 2020 and 2019 amounted to $0 and $146, respectively.

 

Amortization of customer relationships for the three months ended September 30, 2020 and 2019 amounted to $48 and $48, respectively.

 

 

NOTE 8 – OTHER CURRENT LIABILITIES

 

Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:

 

  

September 30,

2020

 

June 30,

2020

Accrued salaries, commissions and payroll taxes  $4,755   $4,492 
Litigation accruals   115    443 
Sales tax payable   1,362    1,353 
Legal and other professional fees   105    113 
Accounting fees   150    120 
Self-funded health insurance reserve   4    87 
Accrued interest and penalty   880    877 
Other   493    700 
Other Current Liabilities  $7,864   $8,185 

 

 Page 18 

 

 FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

NOTE 9 - SEGMENT AND RELATED INFORMATION

 

The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers.

 

The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2020. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.

 

Summarized financial information concerning the Company's reportable segments is shown in the following table:

   Medical
Equipment
  Management
of Diagnostic
Imaging
Centers
  Totals
For the three months ended Sept. 30, 2020               
Net revenues from external customers  $1,981   $18,998   $20,979 
Inter-segment net revenues  $219   $—     $219 
(Loss) Income from operations  $(561)  $4,711   $4,150 
Depreciation and amortization  $67   $901   $968 
Capital expenditures  $20   $415   $435 
                
 For the three months ended Sept. 30, 2019               
Net revenues from external customers  $2,284   $19,463   $21,747 
Inter-segment net revenues  $219   $—     $219 
(Loss) Income from operations  $(736)  $6,222   $5,486 
Depreciation and amortization  $91   $904   $995 
Capital expenditures  $1,601   $848   $2,449 

  

 

NOTE 10 – SUPPLEMENTAL CASH FLOW INFORMATION

 

During the three months ended September 30, 2020 and September 30, 2019, the Company paid $19 and $8 for interest, respectively.

 

During the three months ended September 30, 2020 and September 30, 2019, the Company paid $145 and $228 for income taxes, respectively.

  

 Page 19 

 

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

 

NOTE 11 – COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company.

 

There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2020.

 

Other Matters

 

In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company’s insurance in September 2020. The Company paid the remaining balance of $315 in September 2020.

 

The Company is also delinquent in filing sales tax returns for certain states, for which the Company has transacted business. As of September 30, 2020, the Company has recorded tax obligations of approximately $1,362 plus interest and penalties of approximately $835. The Company is in the process of determining the regulatory requirements in order to become compliant.

 

The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $110 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of September 30, 2020 and June 30, 2020, the Company had approximately $4 and $87, respectively, in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the condensed consolidated balance sheets.

 

The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report.

 Page 20 

 

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

 

NOTE 12 - INCOME TAXES

 

In accordance with ASC 740-270, Income Taxes – Interim Reporting, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur. For the three months ended September 30, 2020 and 2019, the Company recorded income tax expense of $849 in 2020 as compared to $1,107 in 2019. The 2020 provision is comprised of a current income tax component of $0 and a deferred income tax component of $849. Obligations for any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits and utilization of net operating loss carryforwards.

 

ASC topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC topic 740. The Company believes there are no uncertain tax positions in prior years tax filings and therefore it has not recorded a liability for unrecognized tax benefits.

 

In accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net”. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses.

 

The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2016.

 

The Company recorded a deferred tax asset of $17,961 and a deferred tax liability of $234 as of September 30, 2020, primarily relating to net operating loss carryforwards of approximately $49,925 available to offset future taxable income through 2031. The net operating losses begin to expire in 2023 for federal tax and state income tax purposes.

 

 Page 21 

 

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

 

 

NOTE 12 - INCOME TAXES (Continued)

 

On March 27, 2020 Congress enacted the CARES Act (Coronavirus Aid, Relief and Economic Security Act). The Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding prior and future operation losses, temporary changes to prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property and enhanced recoverability of AMT tax credits.

 

At the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.

 

As we continue to monitor tax implications of the CARES Act and other state and federal stimulus tax legislation, we may make adjustments to our estimates and record additional amounts for tax assets and liabilities.

 

Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of September 30, 2020, no such changes in ownership have occurred.

 

The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related to research and development tax credits.

 

A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation.

 

NOTE 13 – SUBSEQUENT EVENTS

 

The Company has evaluated events that occurred subsequent to September 30, 2020 and through the date the condensed consolidated financial statements were issued.

 

 Page 22 

 

FONAR CORPORATION AND SUBSIDIARIES 

 

Item 2. – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

  

For the three month period ended September 30, 2020, we reported a net income of $3.3 million on revenues of $21.0 million as compared to net income of $4.5 million on revenues of $21.7 million for the three month period ended September 30, 2019. Operating income decreased from $5.5 million for the three month period ended September 30, 2019 to $4.2 million for the three month period ended September 30, 2020.

 

The revenue decreased, from $21.7 million for the first three months of fiscal 2020 to $21.0 million for the first three months of fiscal 2021, was primarily due to decreases in patient fee revenue of $1.0 million, from $6.1 million for the first three months of fiscal 2020 to $5.1 million for the first three months of fiscal 2021. Revenues from product sales and service and repair fees decreased by $300,000 from $2.3 million for the first three months of fiscal 2020 to $2.0 million for the first three months of fiscal 2021.

 

While our revenues decreased, our costs and expenses increased, resulting in our operating income decreasing to $4.2 million for the three months ended September 30, 2020 as compared to $5.5 million for the three months ended September 30, 2019. In terms of percentages, costs and expenses increased 3.5% from $16.3 million for the first three months of fiscal 2020 to $16.8 million for the first three months of fiscal 2021, while revenues decreased slightly, from $21.7 million for the first three months of fiscal 2020 to $21.0 million for the first three months of fiscal 2021.

 

Fonar’s wholly owned subsidiary, Health Management Corporation of America (“HMCA”), has the controlling interest, in Health Diagnostics Management, LLC (“HDM”). HMCA presently has a direct ownership interest of 70.0% in HDM, and the investors in HDM have a 30.0% ownership interest. The management of the diagnostic imaging centers business segment is being conducted by HDM, operating under the name “Health Management Company of America”. For the sake of simplicity, HMCA, and HDM are referred to as “HMCA”, unless otherwise indicated.

 

The most significant adverse impact on our Company in fiscal 2020 and the first quarter of fiscal 2021 has been the COVID-19 pandemic. Although it had seemed the worst had passed, events in September and October 2020 have shown a spike in new cases. This is by no means a problem confined to our Company, but regardless of our best efforts, the impact on our results of operation and financial condition is potentially volatile and severe.

 

Since March 2020 the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and economies which have adversely affected our workforce, liquidity, financial conditions, revenues, profitability and business operations. Generally in the beginning COVID-19 caused us to require that much of our workforce work from home and restricted the ability of our personnel to travel for marketing purposes or to service our customers. The Company experienced a sudden drop in scan volume for a short term period and while the Company is not back to pre-COVID-19 levels, the scan volume has risen. During the fourth quarter of fiscal 2020, the Company was able to enact certain decisions to allow the Company to survive during the global pandemic and prevent further losses or additional decreases in scan volume. Although we are unable to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19, particularly in light of recent spikes in new COVID-19 cases, the Company believes with the positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.

 Page 23 

 

FONAR CORPORATION AND SUBSIDIARIES 

 

Forward Looking Statements

 

Certain statements made in this Quarterly Report on Form 10-Q are "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of Management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statement included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved.

 

Results of Operations

 

We operate in two industry segments: the manufacture and servicing of medical (MRI) equipment, which is conducted by Fonar, and diagnostic facilities management services, which is conducted through HMCA.

 

Manufacturing and Service of MRI Equipment

 

Revenues from MRI product sales decreased to $28,000 for the first three months of fiscal 2021 from $192,000 for the first three months of fiscal 2020. Costs related to product sales decreased from $330,000 for the three month period ended September 30, 2019 to $132,000 for the three month period ended September 30, 2020. Economic uncertainty and lower reimbursement rates for MRI scans, have depressed the market for our MRI scanner products, notwithstanding our scanners’ unique technological capabilities (e.g. multi positional scanning). Due to the low sales volumes of out MRI product, period to period comparisons are not necessarily indicative of any trends.

 

Service revenues decreased by 6.6% from $2.1 million for the three month period ended September 30, 2019 to $2.0 million for the three month period ended September 30, 2020. Continuing lower sales volumes have been a factor ultimately contributing to the decrease in service revenues, as the revenue from new scanners being placed under service agreements, following the expiration of their warranties, is insufficient to replace the revenue lost as a result of older scanners being taken out of service.

 

Costs relating to providing service were $760,000 in the first three months of fiscal 2020 and $635,000 in the first three months of fiscal 2021. Because of our ability to monitor the performance of customers’ scanners from our facilities in Melville, New York on a daily basis and to detect and repair any irregularities before more serious and costly problems develop, we have been able to control our costs of providing service.

 

There were approximately $121,000 in foreign revenues for the first three months of fiscal 2021 as compared to approximately $183,000 in foreign revenues for the first three months of fiscal 2020, representing an decrease in foreign revenues of 33.9%. We do not regard this as a material trend, but as part of a normal although sometimes volatile variation resulting from low volumes of foreign sales.

 

 Page 24 

 

 FONAR CORPORATION AND SUBSIDIARIES

  

We recognize MRI scanner sales revenues on the “percentage of completion” basis, which means the revenues are recognized as the scanner is manufactured. Revenues recognized in a particular quarter do not necessarily reflect new orders or progress payments made by customers in that quarter. We build the scanner as the customer meets certain benchmarks in its site preparation in order to minimize the time lag between incurring costs of manufacturing and our receipt of the cash progress payments from the customer which are due upon delivery. Consequently, there can be a disparity between the revenues recognized in a fiscal period and the number of product sales. Generally, the revenues from a scanner sale are recognized in a fiscal quarter or quarters following the quarter in which the sale was made.

 

Revenues for the medical equipment segment decreased to $2.0 million for the first three months of fiscal 2021 from $2.3 million for the first three months of fiscal 2020. Operating losses for our medical equipment segment decreased to an operating loss of $561,000, for the first three months of fiscal 2021 as compared to an operating loss of $736,000 for the first three months of fiscal 2020.

  

Diagnostic Facilities Management Services

 

HMCA revenues decreased in the first three months of fiscal 2021 by 2.4% to $19.0 million from $19.5 million for the first three months of fiscal 2020. The percentage of our revenues derived from our diagnostic facilities management segment relative to the percentage of our revenues derived from our medical equipment segment increased slightly to 90.6% for the first three months of fiscal 2021, from 89.5% for the first three months of fiscal 2020.

 

HMCA’s strategy is to counter the effects of lower reimbursement rates by increasing the scan volume of the facilities it owns or manages by adding additional scanners at current centers and increasing our marketing efforts. As a result of the COVID-19 virus, however, the Company has seen its scan volume decrease. Nevertheless, the Company is continuing its program of adding additional scanners, even though the COVID-19 virus may delay the completion of the installation of some of the scanners. If scan volumes decrease further, or remain at lower volumes, the Company, notwithstanding its ample cash reserves, may need to reduce the size of its operations as a last resort.

 

Although the COVID-19 virus had adversely affected our marketing efforts our scan volumes in fiscal 2020, the number of scans performed at our centers and at our client’s centers has still not recovered to pre-COVID-19 levels and has decreased from approximately 47,000 in the first three months of fiscal 2020 to approximately 42,000 in the first three months of fiscal 2021. Our scan volume began to decline in late March 2020 as a result of the impact of the pandemic on referral sources, stay-at-home orders and travel restrictions. The scan volumes going forward in fiscal 2021 may be adversely affected by additional spikes in the COVID-19 virus if sufficiently severe.

 

We now manage/own a total of 36 MRI scanners. Twenty-two (22) MRI scanners are located in New York and fourteen (14) are located in Florida. HMCA experienced an operating income of $4.7 million for the first three months of fiscal 2021 compared to operating income of $6.2 million for the first three months of fiscal 2020, the decrease being due to greater increase in costs and expenses.

 

The ability of HMCA to maintain its profitability is principally due to HMCA’s success in marketing the scanning services of the facilities managed or owned by HMCA, notwithstanding the decrease in reimbursement rates paid for MRI scans by insurers, Medicare and other government programs and the lockdowns imposed as a result of the COVID-19 virus. The reductions in reimbursement rates are not unique to HMCA or HMCA’s clients but are being experienced by the industry in general.

 

 Page 25 

 

 FONAR CORPORATION AND SUBSIDIARIES

  

HMCA’s cost of revenues for the first three months of fiscal 2021 as compared to the first three months of fiscal 2020 decreased by 8.7% from $10.4 million to $9.5 million primarily as a result of a decrease in scan volume.

 

Consolidated

 

For the first three months of fiscal 2021, our consolidated net revenues decreased by 3.5% to $21.0 million from $21.7 million for the first three months of fiscal 2020, and total costs and expenses increased by 3.5% to $16.8 million from $16.3 million for the first three months of fiscal 2021 and for the first three months of fiscal 2020 respectively. As a result, our operating income decreased to $4.2 million in the first three months of fiscal 2021 as compared to $5.5 million in the first three months of fiscal 2020. An increased selling, general and other administrative costs in particular resulted in the growth of cost and expenses.

 

Selling, general and administrative expenses increased to $6.2 million in the first three months of fiscal 2021 from $4.3 million in the first three months of fiscal 2020. This increase in selling, general and administrative expenses was due mainly to additional reserves taken on Management Fees. Some of these reserves have been taken in the ordinary course of business and some in connection with the impact of the COVID-19 virus. The compensatory element of stock issuances, which is included in selling, general and administrative expenses, remained constant at $0 for the first three months of fiscal 2021 and 2020.

 

Research and development expenses decreased by 18% to $400,000 for the first three months of fiscal 2021 from $472,000 for the first three months of fiscal 2020.

 

Interest expense in the first three months of fiscal 2021 increased by 4.8% to $22,000 from $21,000 in the first three months of fiscal 2020.

 

Inventories increased to $1.7 million at September 30, 2020 as compared to $1.6 million at June 30, 2020.

 

Net management fee and medical receivables increased by 3.6% to $52.3 million at September 30, 2020 from $50.5 million at June 30, 2020 as a result of slower collections. The slower collections were primarily due to an increase in no-fault and workers’ compensation revenue, which typically takes longer to collect.

 

The results of operations for the first three months of fiscal 2021 reflect an decrease in revenues from management, patient and other fees, as compared to the first three months of fiscal 2020 ($19.0 million for the first three months of fiscal 2021 as compared to $19.5 million for the first three months of fiscal 2020), and an decrease in MRI equipment segment revenues ($2.0 million as compared to $2.2 million). Revenues were 9.4% from the MRI equipment segment as compared to 90.6% from HMCA, for the first three months of fiscal 2021, as compared to 10.5% from the MRI equipment segment and 89.5% from HMCA for the first three months of fiscal 2020. 

 

On March 27, 2020, the CARES Act was signed into law and is intended to provide over $2 trillion in stimulus benefits for the U.S. economy. The CARES Act provides for certain federal income tax changes, including an increase in the interest expense tax deduction limitation, the deferral of the employer portion of Social Security payroll taxes, refundable payroll tax credits, net operating loss carryback periods, alternative minimum tax credit refunds and bonus depreciation of qualified improvement property. The federal income tax changes brought about by the CARES Act are complex and further guidance is expected. We received a cash benefit from the ability to receive a full reimbursement of $1,200 of tax credits relating to the alternative minimum tax credits in the current year plus additional cash benefits from the deferral of the employer portion of Social Security payroll taxes.

 

 Page 26 

 

FONAR CORPORATION AND SUBSIDIARIES

 

As a result of the Patient Protection and Affordable Care Act (PPACA) we have experienced a reduction of reimbursement rates and less interest in our MRI equipment. Any changes to the PPACA may result in further changes in the healthcare industry and our business.

 

We are committed to improving our operating results and dealing with the challenges posed by legislative and regulatory requirements. Nevertheless, factors beyond our control, such as the COVID-19 virus, the timing and rate of market growth, economic conditions, the availability of credit and payor reimbursement rates, or unexpected expenditures and the timing of such expenditures, make it difficult to forecast future operating results.

 

As mentioned, one of the effects of the PPACA on our business has been the reduction in Medicare reimbursement rates for MRI scans. This also has resulted in a reduction in the reimbursement rates by commercial insurers and government programs which tie their reimbursement rates to the Medicare rates. Nevertheless, the patient volume of the scanning centers we manage or own has enabled us to maintain healthy operating results in spite of these challenges. We believe we are pursuing the correct policies to cope with these problems and the problems caused by the COVID-19 pandemic, and to improve the Company’s operating results.

 

Our Upright® MRI (also referred to as the Stand-Up® MRI), together with our works-in-progress, are intended to significantly improve our competitive position.

 

The Upright® MRI scanner, which operates at 6000 gauss (.6 Tesla) field strength, allows patients to be scanned while standing, sitting, reclining and in multiple flexion and extension positions. It is common in visualizing the spine that abnormalities are visualized in some positions and not others. This enables surgical corrections that heretofore would not have been addressable for lack of visualizing the symptom causing the pathology and therefore, in general enables the treating physician to achieve a better treatment outcome for his patient. A floor-recessed elevator brings the patient to the height appropriate for the targeted image region. A custom-built multi-position adjustable bed will allow patients to sit or lie on their backs, sides or stomachs at any angle. This allows the MRI technologist to ask the patient to position himself/herself in the exact position that generates his/her pain so that images of the patient in the position that explicitly generates the patient’s pain can be nailed down. Full-range-of-motion studies of the joints in virtually any direction are possible, a particularly promising feature for sports injuries.

 

In addition FONAR has announced the publication of a book “THE CRANIOCERVICAL SYNDROME and MRI” that highlights the unique attributes of FONAR UPRIGHT® MRI Imaging (S. Karger, A.G. based in Basel, Switzerland- www.karger.com/Book/Home/261956) which has been published by S. Karger, an approximately 125 year old company and an academic publisher of scientific and medical journals and books. The seven chapter monograph examines the rapid advances in MRI made possible by the FONAR UPRIGHT® Multi-Position MRI that are transforming the treatment of patients suffering from the craniocervical syndrome (CCS). It is written by leading international experts in the field to practitioners with a better understanding of the subtle anatomy and MRI appearances at the craniocervical junction, along with insight into the clinical significance of cerebrospinal fluid (CSF) flow measurements and its potential role in generating the devastating impairments of the neurodegenerative diseases: Alzheimer’s (5.1 million patients in the United States), childhood and adult Autism (3.0 million), Parkinson’s (1.0 million), Multiple Sclerosis (250,000-350,000) and Amyotrophic Lateral Sclerosis (ALS) (30,000). It calls attention to the revolutionary importance of FONAR’s UPRIGHT® MRI imaging technology and the prospect of significantly relieving the suffering of the above totaled 9.38 million patients afflicted with these disorders.

 

 Page 27 

 

FONAR CORPORATION AND SUBSIDIARIES

 

Fonar also announced a major diagnostic breakthrough in multiple sclerosis achieved with advanced Upright® MRI. Medical researchers at FONAR published a paper reporting a diagnostic breakthrough in multiple sclerosis (MS), based on observations made possible by the Company’s unique Upright® Multi-Position™ MRI scanner. The findings reveal that the cause of multiple sclerosis may be biomechanical and related to earlier trauma to the neck, which can result in obstruction of the flow of cerebrospinal fluid (CSF), which is produced and stored in the central anatomic structures of the brain known as the ventricles. Since the ventricles produce a large net volume of CSF each day (500 cc), the obstruction can result in a build up of pressure within the ventricles, resulting in leakage of the CSF and the antigenic polypeptides it contains into the surrounding brain tissue. This leakage could be responsible for generating the brain lesions of multiple sclerosis.

 

The paper, titled “The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics in the Genesis of Multiple Sclerosis," appears in the journal Physiological Chemistry and Physics and Medical NMR (Sept. 20, 2011).

 

This capability of the Fonar Upright® technology has demonstrated its key value on patients with the Arnold-Chiari syndrome [Cerebellar Tonsil Extopia (CTE)], which is believed to affect 200,000 to 500,000 Americans. In this syndrome, brain stem compression and subsequent severe neurological symptoms occur in these patients, because the brain stem descends and is compressed at the base of the skull in the foramen magnum, which is the circular bony opening at the base of the skull where the spinal cord exits the skull. Conventional lie-down MRI scanners cannot make an adequate evaluation of this pathology since the patient's pathology is most visible and the symptoms most acute when the patient is scanned in the upright fully weight-bearing position.

 

A combined study of 1,200 neck pain patients published in “Brain Injury” (July 2010) by eight university medical centers reported that cerebellar tonsil ectopia (CTE) of 1mm or greater was found and visualized 2.5 times (250%) more frequently when patients who had sustained automobile whiplash injuries were scanned upright rather than lying down.

 

The Upright® MRI has also demonstrated its value for patients suffering from scoliosis. Scoliosis patients have been typically subjected to routine x-ray exams for years and must be imaged upright for an adequate evaluation of their scoliosis. Because the patient must be standing for a complete evaluation of the extent of the patient’s scoliosis, an x-ray machine has been the only modality that could provide that service. The Upright® MRI is the only MRI scanner which allows the patient to stand during the MRI exam. Fonar has developed an RF receiver and scanning protocol that for the first time allows scoliosis patients to obtain diagnostic pictures of their spines without the risks of x-rays. A study by the National Cancer Institute (2000) of 5,466 women with scoliosis reported a 70% increase in breast cancer resulting from 24.7 chest x-rays these patients received on the average in the course of their scoliosis treatment. The Upright® MRI examination of scoliosis enables the needed imaging evaluation of the degree of spine scoliosis without exposing the patient to the risk of breast cancer from x-radiation. Currently scoliosis affects more than 3,000,000 American women.

 

In addition, the University of California, Los Angeles (UCLA) reported their results of their study of 1,302 patients utilizing the Fonar Upright® MRI at the 22nd Annual Meeting of the North American Spine Society on October 23, 2007. The UCLA study showed the superior ability of the Fonar Upright® MRI to detect spine pathology, including spondylolisthesis, disc herniations and disc degeneration, as compared to visualizations of the spine produced by traditional single position static MRIs.

 

 Page 28 

 

FONAR CORPORATION AND SUBSIDIARIES

 

The UCLA study by MRI of 1,302 back pain patients when they were in the Fonar Upright® MRI and examined in a full range of flexion and extension positions made possible by Fonar’s new Upright® technology established that significant “misses” of pathology were occurring with static single position MRI imaging. At L4-5, the vertebral level responsible for 49.8% of lumbar disc herniations, 35.1% of the spondylolistheses (vertebral instabilities) visualized by the Upright® MRI, were being missed by static single position MRI (510 patients). Since this vertebral segment is responsible for the majority of all disc herniations, the finding may reveal a significant cause of failed back surgeries. The UCLA study further showed the “miss-rate” of vertebral instabilities by static only MRI was even higher, 38.7%, at the L3-4 vertebral segment. Additionally, the UCLA study showed that MRI examinations of the cervical spine that did not perform extension images of the neck “missed” disc bulges 23.75% of the time (163 patients).

 

The UCLA study further reported that they were able to quantitatively measure the dimensions of the central spinal canal with the “highest accuracy” using the FONAR Upright® MRI thereby enabling the extent of spinal canal stenosis that existed in patients to be measured. Spinal canal stenosis gives rise to the symptom complex intermittent neurogenic claudication manifest as debilitating pain in the back and lower extremities, weakness and difficulties in ambulation and leg paresthesias. Spinal canal stenosis is a spinal compression syndrome separate and distinct from the more common nerve compression syndrome of the spinal nerves as they exit the vertebral column through the bony neural foramen.

 

The Fonar Upright® MRI can also be useful for MRI directed emergency neuro-surgical procedures as the surgeon would have unhindered access to the patient’s head when the patient is supine with no restrictions in the vertical direction. This easy-entry, mid-field-strength scanner could prove ideal for trauma centers where a quick MRI-screening within the first critical hour of treatment will greatly improve patients’ chances for survival and optimize the extent of recovery.

 

 MRI has brought a new dimension to MEDICAL TREATMENT, the power to VISUALIZE ANATOMIC DETAIL in the body's VITAL SOFT TISSUES (brain, heart, kidney, liver, spleen, lungs, pancreas, intestines) plus MRI's new power to non-invasively QUANTIFY (e.g. measure T1, T2, diffusion, chemical spectra) the response of these VITAL TISSUES to treatment.

 

Liquidity and Capital Resources

 

Cash and cash equivalents, and short term investments increased by 5.3% from $36.8 million at June 30, 2020 to $38.8 million at September 30, 2020.

 

Cash provided by operating activities for the first three months of fiscal 2021 was $3.8 million. Cash provided by operating activities was attributable principally to net income of $3.3 million, depreciation and amortization of $968,000, amortization on right-to-use assets of $953,000, provision for bad debts of $2.2 million and deferred income tax of $849,000, offset by an increase in accounts, management fee receivables and medical receivables of $4.1 million and a decrease in operating lease liabilities of $796,000. 

 

Cash used by investing activities for the first three months of fiscal 2021 was $435,000. Cash used by investing activities was attributable during the first three months of fiscal 2021 consisted of patent costs of $20,000 and the purchase of property and equipment of $415,000.

 

Cash used in financing activities for the first three months of fiscal 2021 was $1.4 million. The principal uses of cash in financing activities during the first three months of fiscal 2021 were the repayment of principal on long-term debt and capital lease obligations of $9,000 and distributions to non-controlling interests of $1.4 million, offset by the proceeds from debt of $63,000. 

 Page 29 

 

 FONAR CORPORATION AND SUBSIDIARIES

 

Total liabilities decreased by 1.5% to $53.2 million at September 30, 2020 from $54.0 million at June 30, 2020. “Other” current liabilities decreased by 3.9% to $7.9 million at September 30, 2020 from $8.2 million at June 30, 2020. Long-term debt and capital lease obligations remained constant at $2.1 million. The current portion of our unearned revenue on service contracts increased from $4.1 million to $4.2 million. Customer deposits increased from $855,000 at June 30, 2020 to $912,000 at September, 2020 as a result of an increase in services performed.

 

As of September 30, 2020, the total of $7.9 million in “other” current liabilities included accrued salaries and payroll taxes of $4.8 million, and sales taxes of $1.4 million plus accrued interest and penalties of $880,000.

 

Our working capital increased to $80.5 million at September 30, 2020 from $77.2 million at June 30, 2020. This resulted from an increase in current assets ($95.9 million at June 30, 2020 as compared to $99.1 million at September 30, 2020), and a small decrease in current liabilities from $18.7 million at June 30, 2020 to $18.6 million at September 30, 2020.

    

The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry, and tax planning strategies in making this assessment. At the present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, (principally related to research and development tax credits and allowance for doubtful accounts). A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of any portion or all of the valuation allowance.

 

The Company’s effective income tax rate is based on expected income, statutory rates and tax planning opportunities available in the various jurisdictions in which it operates. For interim financial reporting, the Company estimates the annual income tax rate based on projected taxable income for the full year and records a quarterly income tax provision or benefit in accordance with the anticipated annual rate. The Company refines the estimates of the year’s taxable income on a periodic basis as new information becomes available, including actual year-to-date financial results. This continual estimation process often results in a change to the expected effective income tax rate for the year. When this occurs, the Company adjusts the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date provision reflects the expected income tax rate. Significant judgment is required in determining the effective tax rate and in evaluating tax positions.

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled in exchange for goods and services as it transfers control to its customers. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The Company earns revenue from the sale of scanners, maintenance contracts, product upgrades, patient services and management fees. Under the new guidance, the reporting for patient services revenue is now reported differently. All other streams of revenue were not impacted by the new guidance. The primary change for healthcare providers under the new guidance relates to revenue generated from patient services, with patient responsibility for payment. Under the new guidance, the Company is required to report an implicit price concession (both initially and for the subsequent changes in estimates) as a reduction of revenues as opposed to bad debt expense as a component of operating expenses. The Company now records any changes in expectation of collection amounts due to patient specific events that suggests that the patient no longer has the ability and intent to pay the amount due through the bad debt expense, as that is more indicative of a change in the customer’s credit worthiness as opposed to change in the transaction price.

 

 Page 30 

 

 FONAR CORPORATION AND SUBSIDIARIES

  

The new standard supersedes most current revenue guidance, including industry-specific guidance. The guidance became effective for the Company on July 1, 2018 and as part of adopting the standard, the Company identified revenue streams of like contracts to allow for ease of implementation. The Company used primarily a portfolio approach to apply the new model to classes of customers with similar characteristics. The impact of adopting the new standard on our total revenue; and income from operations was not material. While the adoption of ASU 2014-09 did impact the presentation of net operating revenues in our Consolidated Statements of Operations and impacts certain disclosures, it did not materially impact our financial position, results of operations or cash flows. There was no cumulative effect of a change in accounting principle recorded related to the adoption of ASU 2014-09 on July 1, 2018.

 

On March 27, 2020 Congress enacted the CARES Act (Coronavirus Aid, Relief and Economic Security Act). The Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding prior and future operating losses, temporary changes to the prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property and the creation of refundable employee retention credits. At the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1,200 of tax credits relating to the alternative minimum tax credits in the current year. Before the CARES Act, these credits were to be refunded over a period of 3 years. We will also realize a cash benefit from the deferral of Social Security payroll taxes.

 

On June 30, 2020, we entered into a $701,000 loan agreement under the Paycheck Protection Program (PPP) under the CARES Act that provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses. The Company applied for this additional loan exclusively for the Florida locations during June 2020 due to the fact that the COIVD-19 virus was increasing in Florida. The loans and accrued interest are forgivable after 24 weeks as long as the proceeds are used for eligible purposes, including payroll, benefits, rent and utilities and maintains certain payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the 24 week period. The Company believes that most it not all of the loan proceeds will be forgiven, however there is no assurance that it will be forgiven until approval is received.

 

Fonar has not committed to making any significant capital expenditures for the remainder of the 2021 fiscal year with the exception of placing additional scanners at 3 facilities located in New York.

 

Critical to our business plan are the improvement and expansion of the MRI facilities managed or owned by HMCA, and increasing the number of scans performed at those facilities. In addition, our business plan calls for a continuing commitment to providing our customers with enhanced equipment service and maintenance capabilities and delivering state-of-the-art, innovative and high quality equipment and upgrades at competitive prices.

 

 Management is seeking to promote wider market recognition of Fonar’s scanner products, and to increase demand for Upright® scanning at the facilities HMCA owns or manages. Given the liquidity and credit constraints in the markets, the uncertainty resulting from the Patient Protection and Affordable Care Act or its repeal or modification, and the impact of the COVID-19 virus on the economy in general, the sale of medical equipment has and may continue to suffer.

 

 Page 31 

 

 FONAR CORPORATION AND SUBSIDIARIES

 

The Company believes that its business plan has been responsible for the past eight consecutive fiscal years and first fiscal quarter of fiscal 2021 of profitability and that its capital resources will be adequate to support operations through at least September 30, 2021. The future effects on our business of healthcare legislation, the impact of the COVID-19 virus, the Deficit Reduction Act, the 2.3% excise tax on sales of medical equipment, reimbursement rates, public health conditions and the general economic and business climate are not known at the present time. Nevertheless, there is a possibility of adverse consequences to our business operations from these causes. Although the Company can not predict the full effect of COVID-19 for the first fiscal quarter or any later period, the Company believes that it has adequate revenues, cash reserves and other assets that will enable it to continue to operate until at least September 30, 2021.

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

The Company maintains its funds in liquid accounts. None of our investments are in fixed rate instruments.

 

All of our revenue, expense and capital purchasing activities are transacted in United States dollars.

 

   

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

We carried out an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the ‘‘Exchange Act’’). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based upon our evaluation, our chief executive officer and chief financial officer has concluded that the Company’s internal control over financial reporting was effective as of the September 30, 2020, in ensuring that material information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the same time periods specified in the Securities and Exchange Commission rules and forms.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our system of internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 Page 32 

 

 FONAR CORPORATION AND SUBSIDIARIES

 

PART II – OTHER INFORMATION

 

Item 1 – Legal Proceedings: There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2020.

 

Item 1A – Risk Factors: An investment in the securities of the Company is subject to various risks, the most significant of which are summarized below.

 

1. Reduced Reimbursement Rates. Most of our revenues are derived from our scanning center business conducted by HMCA. Our scanning center clients and the Florida facilities owned by HMCA are experiencing lower reimbursement rates from Medicare, other government programs and private insurance companies. To date, the impact of these reductions has been countered by increasing scanning volume, increased reimbursement rates with other payors, and reducing our operating expenses, thereby maintaining profitability in this business segment. There is, however, no assurance that we will be able to continue to do so.

 

2. Demand for MRI Scanners. The reduced reimbursement rates also affects our sales of MRI scanners negatively. With lower revenue projections, fewer prospective customers will be able to operate, and others are likely to demand lower prices for scanners. Although the reduced reimbursements may not affect foreign demand, a lower number of sales in the aggregate could reduce economies of scale and consequently, profit margins. The demand for MRI scanners could be further reduced by any downturn in the economy resulting from the COVID-19 virus.

 

3. Manufacturing Competition. Many if not most of our competing scanner manufacturers have significantly greater financial resources, production capacity, and other resources than we do. Such competitors would include General Electric, Siemens, Hitachi and Phillips. Although Fonar is the only company which can manufacture and sell the unique Stand-Up® (Upright®) MRI scanner, potential customers must be convinced that the purchase of a Fonar scanner is their best choice. We believe that with time, that objective will be reached, particularly with customers scanning patients having neck, back, knee and various orthopedic issues who would benefit from being scanned in weight-bearing positions.

 

4. Dependence on Referrals. HMCA derives substantially all of its revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at the facilities. We depend on referrals of patients from unaffiliated physicians and other third parties to the facilities we manage or own for the MRI scanning services performed. If these physicians and other third parties were to reduce the number of patients they refer or discontinue referring patients, scan volumes could decrease, which would have the effect of reducing our net revenue, from both management and scanning fees, and operating margins.

 

5. Pressure to Control Healthcare Costs. One of the principal objectives of health maintenance organizations and preferred provider organizations is to control the cost of healthcare services. Healthcare providers participating in managed care plans may be required to refer diagnostic imaging tests to certain providers depending on the plan in which a covered patient is enrolled. In addition, managed care contracting has become very competitive. The expansion of health maintenance organizations, preferred provider organizations and other managed care organizations in New York or Florida could have a negative impact on the utilization and pricing of services performed at the facilities HMCA manages or owns to the extent these organizations exert control over patients’ access to diagnostic imaging services, selections of the provider of such services and reimbursement rates for those services.

 

 Page 33 

 

 FONAR CORPORATION AND SUBSIDIARIES

 

6. Scanning Facility Competition. The market for diagnostic imaging services is highly competitive. The facilities we manage or own compete for patients on the basis of reputation, location and the quality of diagnostic imaging services. Groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment are the principal competitors.

 

7. Eligibility Changes to Insurance Programs. Due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured or participate in governmental programs may increase. Healthcare reform legislation may increase the participation of individuals in the Medicaid program in states that elect to participate in the expanded Medicaid coverage, subject to any changes which may result from efforts to repeal and replace the PPACA. A shift in payor mix from managed care and other private payors to government payors or an increase in the number of uninsured patients may result in a reduction in the rates of reimbursement or an increase in uncollectible receivables or uncompensated care, with a corresponding decrease in net revenue. Policies now being offered under various insurance plans are expected to reduce demand for MRI scans as they become less affordable. Changes in the eligibility requirements for governmental programs such as the Medicaid program and state decisions on whether to participate in the expansion of such programs also could increase the number of patients who participate in such programs and the number of uninsured patients. Even for those patients who remain in private insurance plans, changes to those plans could increase patient financial responsibility, resulting in a greater risk of uncollectible receivables. These factors and events could have a material adverse effect on our business, financial condition, and results of operations.

 

8. Possible changes in Florida Insurance Law. In early 2019, two senate bills and one house bill in Florida were introduced, all of them calling for the repeal of PIP and replacing PI with $25,000 Bodily Injury Coverage and Property Damage Liability Coverage. Another Florida senate bill was introduced that would preserve PIP but dramatically cut reimbursement rates. None of the proposed bills ever made it onto the 2019 legislative agenda, but similar efforts in the future might be successful. Currently, drivers and passengers get car damages and PIP paid for up to $10,000, no matter who is at fault in an accident. Drivers have to pay an additional cost to insurance companies to pay for bodily injuries, which covers them if they are at fault. While PIP is required, coverage for bodily injury is not. Over the past several years there have been various bills introduced by a number of Florida legislators to eliminate PIP and instead mandate coverage including some combination of a minimum of bodily injury and a reduced or no amount of medical payments (Medpay coverage). Eliminating PIP would mean that the $10,000 drivers now get paid toward medical costs through their insurers might not be there for them to pay for injured drivers. Importantly, payments would be reduced by approximately 60% due to claims being paid at commercial rates or through legal settlements instead of at the presently prevailing PIP fee schedule. This would negatively impact our eight diagnostic imaging facilities (both those we own and those we manage) with more unpaid bills, lower reimbursement rates and elongated waiting times. The recent bills, which were introduced in 2020, gained no traction.

 

9. Federal and state privacy and information security laws. We must comply with numerous federal and state laws and regulations governing the collection, dissemination, access, use, security and privacy of Protected Health Information (‘PHI’), including Health Insurance Portability and Accountability Act (‘HIPAA’) and its implementing privacy and security regulations, as amended by the federal Health Information Technology for Economic and Clinical Health (‘HITECH’) Act and collectively referred to as HIPAA. If we fail to comply with applicable privacy and security laws, regulations and standards, properly maintain the integrity of our data, protect our proprietary rights to our systems, or defend against cybersecurity attacks, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.

 

Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the use of the internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state agents. Our operations rely on the secure processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks.

 Page 34 

 

FONAR CORPORATION AND SUBSIDIARIES

 

10. COVID-19. Although we believe we have taken the proper steps and are making a good recovery from the impact of COVID-19 virus, the recent increase in new cases of COVID-19 and the course and severity of the virus in the following months, may have an economic and medical impact that would materially and adversely affect our business.

 

11. Other changes in Domestic and Worldwide Economic Conditions. We are subject to risk arising from adverse changes in general domestic and global economic and other conditions, including a prolonged period of the COVID-19 pandemic, recessions or economic slowdowns and disruptions of credit markets. Turbulence and uncertainty in the United States and international markets and economies may adversely affect our workforce, liquidity, financial condition, revenues, profitability and business operations generally.

 

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds: None

 

Item 3 - Defaults Upon Senior Securities: None

 

Item 4 - Mine Safety Disclosure: Not Applicable

 

Item 5 - Other Information: None 

  

Item 6 - Exhibits and Reports on Form 8-K:

  

c) 

Exhibit 31.1 Certification. See Exhibits

 

b) 

Exhibit 32.1 Certification. See Exhibits

 

c)  Report on Form 8-K filed on September 29, 2020, Item 2.02: Results of Operations and Financial Condition for the fiscal year ended June 30, 2020.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

FONAR CORPORATION

(Registrant)

 

________________

By: /s/ Timothy Damadian

Timothy Damadian

President and

Principal Executive Officer

 

________________

/s/ Raymond V. Damadian

Raymond V. Damadian

Chairman of the Board,

Treasurer and

Acting Principal Financial Officer

  

Dated: November 12, 2020 

 Page 35 

 

  

GRAPHIC 2 fonar-logo.jpg GRAPHIC begin 644 fonar-logo.jpg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end EX-31.1 3 fonar_exhibit-31.htm SECTION 302 CERTIFICATION

Exhibit 31.1

 

CERTIFICATION

 

 

Timothy Damadian and Raymond V. Damadian each certify that:

 

1.I have reviewed this report on Form 10-Q of Fonar Corporation;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f) for the registrant and have:

 

a)designed such disclosure controls and procedures or caused such disclosure controls over procedures to be designed under my supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report; and

 

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

 

 

 

Date: November 12, 2020

 

 

____________________________

/s/ Timothy Damadian

Timothy Damadian

President and

Principal Executive Officer

 

 

____________________________

/s/ Raymond V. Damadian

Raymond V. Damadian

Chairman of the Board, Treasurer and

Acting Principal Financial Officer

 

EX-32.1 4 fonar_exhibit-32.htm SECTION 906 CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of FONAR Corporation and Subsidiaries (the “Company”) on Form 10Q for the fiscal quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy Damadian, President and Chief Executive Officer, and I, Raymond V. Damadian, Chairman of the Board, Treasurer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

 

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

/s/Timothy Damadian

 

 

____________________________

Timothy Damadian

President and Chief Executive Officer

 

/s/ Raymond V. Damadian

 

 

____________________________

Raymond V. Damadian

Chairman of the Board, Treasurer and

Chief Financial Officer

 

 

November 12, 2020

 

A signed original of this written statement required by Section 906 has been provided to Fonar Corporation and will be retained by Fonar Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-101.INS 5 fonr-20200930.xml XBRL INSTANCE FILE 0000355019 2020-06-30 0000355019 2020-09-30 0000355019 2019-07-01 2019-09-30 0000355019 2020-07-01 2020-09-30 0000355019 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000355019 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000355019 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000355019 us-gaap:CommonClassCMember 2020-07-01 2020-09-30 0000355019 us-gaap:CommonClassCMember 2019-07-01 2019-09-30 0000355019 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000355019 FONR:MedicalEquipmentMember 2020-07-01 2020-09-30 0000355019 FONR:MedicalEquipmentMember 2019-07-01 2019-09-30 0000355019 FONR:ManagementOfDiagnosticImagingCentersMember 2020-07-01 2020-09-30 0000355019 FONR:ManagementOfDiagnosticImagingCentersMember 2019-07-01 2019-09-30 0000355019 us-gaap:CommonStockMember 2020-11-06 0000355019 FONR:ClassANonVotingPreferredStockMember 2020-11-06 0000355019 us-gaap:CommonClassCMember 2020-11-06 0000355019 us-gaap:CommonClassBMember 2020-11-06 0000355019 us-gaap:AccountsReceivableMember 2020-06-30 0000355019 us-gaap:AccountsReceivableMember 2020-09-30 0000355019 us-gaap:DoubtfulMember 2020-06-30 0000355019 us-gaap:DoubtfulMember 2020-09-30 0000355019 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-06-30 0000355019 FONR:PatentsAndCopyrightsMember 2020-06-30 0000355019 us-gaap:NoncompeteAgreementsMember 2020-06-30 0000355019 us-gaap:CustomerRelationshipsMember 2020-06-30 0000355019 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-09-30 0000355019 FONR:PatentsAndCopyrightsMember 2020-09-30 0000355019 us-gaap:NoncompeteAgreementsMember 2020-09-30 0000355019 us-gaap:CustomerRelationshipsMember 2020-09-30 0000355019 FONR:PatentsAndCopyrightsMember 2020-07-01 2020-09-30 0000355019 FONR:PatentsAndCopyrightsMember 2019-07-01 2019-09-30 0000355019 us-gaap:NoncompeteAgreementsMember 2020-07-01 2020-09-30 0000355019 us-gaap:NoncompeteAgreementsMember 2019-07-01 2019-09-30 0000355019 us-gaap:CustomerRelationshipsMember 2020-07-01 2020-09-30 0000355019 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-09-30 0000355019 us-gaap:CommonStockMember 2020-09-30 0000355019 us-gaap:CommonStockMember 2020-06-30 0000355019 FONR:WorkersCompensationPersonalInjuryMember 2019-07-01 2019-09-30 0000355019 FONR:WorkersCompensationPersonalInjuryMember 2020-07-01 2020-09-30 0000355019 FONR:MedicareMedicaidMember 2019-07-01 2019-09-30 0000355019 FONR:MedicareMedicaidMember 2020-07-01 2020-09-30 0000355019 FONR:CommercialInsuranceManagedCareMember 2019-07-01 2019-09-30 0000355019 FONR:CommercialInsuranceManagedCareMember 2020-07-01 2020-09-30 0000355019 FONR:OtherRevenueSourceMember 2020-07-01 2020-09-30 0000355019 FONR:OtherRevenueSourceMember 2019-07-01 2019-09-30 0000355019 FONR:ClassANonVotingPreferredStockMember 2020-09-30 0000355019 us-gaap:PreferredStockMember 2020-09-30 0000355019 FONR:ClassANonVotingPreferredStockMember 2020-06-30 0000355019 us-gaap:PreferredStockMember 2020-06-30 0000355019 us-gaap:CommonClassBMember 2020-09-30 0000355019 us-gaap:CommonClassCMember 2020-09-30 0000355019 us-gaap:CommonClassBMember 2020-06-30 0000355019 us-gaap:CommonClassCMember 2020-06-30 0000355019 FONR:ClassANonVotingPreferredStockMember 2019-07-01 2019-09-30 0000355019 FONR:ClassANonVotingPreferredStockMember 2020-07-01 2020-09-30 0000355019 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000355019 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000355019 us-gaap:CommonStockMember 2020-06-30 0000355019 us-gaap:CommonStockMember 2020-09-30 0000355019 us-gaap:CommonStockMember 2019-06-30 0000355019 us-gaap:CommonStockMember 2019-09-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000355019 us-gaap:RetainedEarningsMember 2020-06-30 0000355019 us-gaap:RetainedEarningsMember 2020-09-30 0000355019 us-gaap:RetainedEarningsMember 2019-06-30 0000355019 us-gaap:RetainedEarningsMember 2019-09-30 0000355019 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000355019 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000355019 us-gaap:TreasuryStockMember 2020-06-30 0000355019 us-gaap:TreasuryStockMember 2020-09-30 0000355019 us-gaap:TreasuryStockMember 2019-06-30 0000355019 us-gaap:TreasuryStockMember 2019-09-30 0000355019 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000355019 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000355019 us-gaap:NoncontrollingInterestMember 2020-06-30 0000355019 us-gaap:NoncontrollingInterestMember 2020-09-30 0000355019 us-gaap:NoncontrollingInterestMember 2019-06-30 0000355019 us-gaap:NoncontrollingInterestMember 2019-09-30 0000355019 2019-06-30 0000355019 2019-09-30 0000355019 FONR:HDMMember 2015-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 3299000 2508000 3299000 3097000 2355000 39000 51000 2508000 151000 114000 15878000 15970000 6447463 313438 382513 146 8000 19000 228000 145000 6432000 6447000 6432000 6447000 383000 383000 0.51 0.39 0.48 0.37 0.10 0.13 0.47 0.36 0.10 0.13 6560000 6575000 383000 383000 19987000 20006000 7005000 5082000 4100000 3800000 7005000 5101000 4100000 3800000 45000 47000 0 146000 48000 48000 128000 128000 128000 128000 110000 835000 1362000 309000 309000 757000 757000 234000 448000 448000 0 849000 1107000 849000 1544000 1537000 105000 161000 1000 1000 6045000 5091000 4294000 3387000 266000 197000 1354000 946000 561000 131000 17961000 0.0001 0.001 0.0001 0.001 453000 567000 453000 567000 313000 313000 313000 313000 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 8500000 8500000 227000 567000 227000 567000 6459000 6459000 146 383000 146 383000 6447000 6447000 146 383000 146 383000 827000 827000 228000 2761000 879000 1991000 1755000 1440000 1440000 1755000 -1207000 -743000 -743000 -1207000 FONAR CORP 0000355019 10-Q 2020-09-30 2021 --06-30 Q1 false 0-10248 DE Yes Yes true Non-accelerated Filer false FONR NASDAQ Common Stock 153000 153000 false -140000 126242000 128053000 1000 1000 1000 1000 183076000 183076000 181086000 183076000 -56215000 -53707000 -64456000 -61157000 -675000 -675000 -675000 -675000 55000 -642000 2156000 1608000 118112000 122854000 49925000 95890000 99124000 1758000 1879000 153000 153000 1649000 1698000 6000 102000 32000 32000 36802000 38763000 180259000 181256000 653000 642000 4109000 4036000 3985000 3985000 1326000 1276000 31392000 30489000 21364000 20904000 18810000 17961000 2730000 2839000 18663000 18648000 855000 912000 75000 136000 3370000 3433000 83000 4105000 4203000 1965000 1848000 108000 169000 54017000 53203000 35354000 34555000 150000 161000 865000 859000 1251000 1201000 30105000 29246000 93000 93000 234000 234000 2656000 2761000 180259000 181256000 55000 -642000 126187000 128695000 -56215000 -53707000 675000 675000 16261000 16829000 4294000 6163000 472000 400000 1537000 1428000 6005000 5550000 10000 9000 750000 626000 330000 132000 2863000 2521000 21747000 20979000 2390000 2693000 11028000 11214000 28000 28000 2064000 1925000 192000 28000 1107000 849000 5613000 4100000 148000 112000 21000 22000 5486000 4150000 0.10 0.13 383000 383000 -2568000 -435000 38000 20000 119000 2411000 415000 4243000 3782000 -13000 10000 -62000 58000 -750000 -796000 -2889000 -36000 -345000 -117000 44000 -7000 49000 -218000 -14000 1188000 4109000 1004000 849000 -239000 2227000 819000 953000 995000 968000 4506000 3251000 36802000 38763000 13882000 13794000 -88000 1961000 -1763000 -1386000 63000 8000 9000 -671000 1000 12000 6896000 7002000 10218000 10782000 3322000 3780000 27438000 29011000 38501000 41844000 11063000 12833000 16172000 16293000 16172000 16293000 0 0 6000 102000 6000 102000 0 0 4313000 4191000 4828000 4706000 515000 515000 16172000 16172000 0 0.67 0.66 0.11 0.128 32679000 9331000 18545000 4390000 4485000 4698000 4847000 5045000 1337000 169000 408000 244000 244000 244000 244000 122000 8185000 7864000 700000 493000 877000 880000 87000 4000 120000 150000 113000 105000 1353000 1362000 443000 115000 4492000 4755000 2449000 435000 20000 1601000 415000 848000 995000 968000 67000 91000 901000 904000 5486000 4150000 -561000 -736000 4711000 6222000 219000 219000 219000 219000 21747000 20979000 1981000 2284000 18998000 19463000 In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company’s insurance in September 2020. The Company paid the remaining balance of $315 in September 2020. Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period. -604000 -604000 202268000 33300000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">NOTE 1 &#8211; DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Description of Business</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name &#8220;Health Management Company of America&#8221;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basis of Presentation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K filed on October 1, 2020 for the fiscal year ended June 30, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During March 2020 the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and economies which has adversely effected our workforce, liquidity, financial conditions, revenues, profitability and business operations. Generally COVID-19 had caused us to require that much of our workforce work from home and has restricted the ability of our personnel to travel for marketing purposes or to service our customers. The Company experienced a sudden drop in scan volume for a short term period and while the Company is not back to pre-COVID-19 levels, the volume has risen. At the end of fiscal year ending June 30, 2020, the Company was able to enact certain decisions to allow the Company to survive during the global pandemic and from further losses or additional decreases in scan volume. The Company immediately enacted wide scale furloughs, deferment of up to 50% of management salaries, halted variable compensation plans and rent deferrals we negotiated with the majority of all landlords. The Company also received some government stimulus funds from the Paycheck Protection Program (&#8220;PPP&#8221;) and Medicare advances/stimulus payments. Although we are unable to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19, the Company believes with positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 3 &#8211; ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Receivables, net is comprised of the following at September 30, 2020, and June 30, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">September 30, 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Gross Receivable</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Allowance for doubtful accounts</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Net</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Accounts receivable</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">4,706</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">515</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">4,191</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Accounts receivable - related party</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">102</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">102</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Medical receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,293</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,293</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Management and other fees receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">41,844</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12,833</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">29,011</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,782</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,780</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,002</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Gross Receivable</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Allowance for doubtful accounts</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Net</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Accounts receivable</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">4,828</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">515</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">4,313</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Accounts receivable - related party</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Notes receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,172</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,172</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Medical receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,172</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,172</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Management and other fees receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">38,501</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,063</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">27,438</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,218</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,322</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,896</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s customers are concentrated in the healthcare industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Accounts Receivable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Credit risk with respect to the Company&#8217;s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long Term Accounts Receivable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be recognized over the following four years at September 30, 2020 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><font style="font-size: 10pt">2022</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">879</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">827</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">2024</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">827</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">2025</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">228</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,761</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Medical Receivables</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient&#8217;s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management&#8217;s best estimate of the amounts that will not be collected. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management and Other Fees Receivable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s receivables from the related and non-related professional corporations (PC&#8217;s) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PC&#8217;s of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment of the management fee receivables from the PC&#8217;s may be impaired by the inability of the PC&#8217;s to collect in a timely manner their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 66% and 67% of the PCs&#8217; net revenues for the three months ended September 30, 2020 and 2019, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically been within management&#8217;s expectations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net revenues from management and other fees charged to the related PCs accounted for approximately 12.8% and 11.0% of the consolidated net revenues for the three months ended September 30, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI &#38; Diagnostic Center, PA (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s patient fee revenue, net of contractual allowances and discounts for the three months ended September 30, 2020 and 2019 are summarized in the following table.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">For the Three Months Ended <br /> September 30,</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Commercial Insurance/ Managed Care</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">946</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">1,354</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Medicare/Medicaid</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">197</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">266</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Workers&#8217; Compensation/Personal Injury</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,387</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,294</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Other</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">561</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">131</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Patient Fee Revenue, net of contractual allowances and discounts</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,091</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,045</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: -9pt">NOTE 4 &#8211; OPERATING &#38; FINANCING LEASES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: -9pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During February 2016, FAS issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Lease with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard was effective for us beginning July 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We have also elected the transition package of the practical expedients permitted within the standard which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and indirect costs. The adoption of this guidance had a material impact on the Company&#8217;s balance sheet by virtue of including the present value of its future operating lease payments as a liability of $33.3 million and related right-to-use lease assets as of July 1, 2019. At the time of adoption of this guidance we had no significant financing leases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: -9pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for its various operating leases in accordance with Accounting Standards Codification (&#8216;ASC&#8217;) 842 &#8211; Lease, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Also included in other current assets is a $202,268 receivable from a landlord for tenant improvements. Our incremental borrowing rate (&#8220;IBR&#8221;) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of September 30, 2020 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Year Ending <br /> September 30,</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Operating Lease <br /> Payments</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Financing Lease Payments</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; text-align: center"><font style="font-size: 10pt">2021</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 27%; text-align: right"><font style="font-size: 10pt">5,045</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 27%; text-align: right"><font style="font-size: 10pt">122</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,847</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">244</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,698</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">244</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">2024</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,485</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">244</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">2025</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,390</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">244</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">Thereafter</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">18,545</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">408</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">Present value discount</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(9,331</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(169</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: center"><font style="font-size: 10pt">Total lease liability</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">32,679</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,337</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: -9pt">NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: -9pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">Information relating to uncompleted contracts is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">September 30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">June 30,<br /> &#160;2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Costs incurred on uncompleted contracts</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">448</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">448</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Estimated earnings</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">309</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">309</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Subtotal</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">757</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">757</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Less: Billings to date</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">604</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">604</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Total Costs and estimated earnings in excess of billings on uncompleted contracts</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">153</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">153</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 7 &#8211; OTHER INTANGIBLE ASSETS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">September&#160;30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">June 30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%"><font style="font-size: 10pt">Capitalized software development costs</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">7,005</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">7,005</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Patents and copyrights</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,101</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,082</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Non-compete</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,100</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,100</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Customer relationships</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3,800</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3,800</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross Other intangible assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">20,006</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">19,987</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Less: Accumulated amortization</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">15,970</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">15,878</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Other Intangible Assets</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,036</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,109</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of patents and copyrights for the three months ended September 30, 2020 and 2019 amounted to $45 and $47, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of non-compete for the three months ended September 30, 2020 and 2019 amounted to $0 and $146, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization of customer relationships for the three months ended September 30, 2020 and 2019 amounted to $48 and $48, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 8 &#8211; OTHER CURRENT LIABILITIES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">September&#160;30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">June 30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Accrued salaries, commissions and payroll taxes</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">4,755</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">4,492</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Litigation accruals</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">115</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">443</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Sales tax payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,362</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,353</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Legal and other professional fees</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">105</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">113</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Accounting fees</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">150</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">120</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Self-funded health insurance reserve</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">87</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Accrued interest and penalty</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">880</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">877</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Other</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">493</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">700</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Other Current Liabilities</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,864</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,185</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">NOTE 9 - SEGMENT AND RELATED INFORMATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company&#8217;s 10-K as of June 30, 2020. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Summarized financial information concerning the Company&#8217;s reportable segments is shown in the following table:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Medical <br /> Equipment</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Management <br /> of Diagnostic <br /> Imaging <br /> Centers</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Totals</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">For the three months ended Sept. 30, 2020</font></td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%"><font style="font-size: 10pt">Net revenues from external customers</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">1,981</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">18,998</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">20,979</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Inter-segment net revenues</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">219</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">219</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">(Loss) Income from operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(561</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,711</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,150</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Depreciation and amortization</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">67</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">901</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">968</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Capital expenditures</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">20</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">415</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">435</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">&#160;For the three months ended Sept. 30, 2019</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Net revenues from external customers</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2,284</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">19,463</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">21,747</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Inter-segment net revenues</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">219</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">219</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">(Loss) Income from operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(736</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">6,222</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,486</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Depreciation and amortization</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">91</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">904</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">995</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Capital expenditures</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,601</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">848</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2,449</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">NOTE 10 &#8211; SUPPLEMENTAL CASH FLOW INFORMATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2020 and September 30, 2019, the Company paid $19 and $8 for interest, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2020 and September 30, 2019, the Company paid $145 and $228 for income taxes, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 11 &#8211; COMMITMENTS AND CONTINGENCIES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Litigation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other Matters</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company&#8217;s insurance in September 2020. The Company paid the remaining balance of $315 in September 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is also delinquent in filing sales tax returns for certain states, for which the Company has transacted business. As of September 30, 2020, the Company has recorded tax obligations of approximately $1,362 plus interest and penalties of approximately $835. The Company is in the process of determining the regulatory requirements in order to become compliant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $110 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of September 30, 2020 and June 30, 2020, the Company had approximately $4 and $87, respectively, in reserve for its self-funded health insurance programs. The reserves are included in &#8220;Other current liabilities&#8221; in the condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims&#8217; incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">NOTE 13 &#8211; SUBSEQUENT EVENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated events that occurred subsequent to September 30, 2020 and through the date the condensed consolidated financial statements were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Summarized financial information concerning the Company&#8217;s reportable segments is shown in the following table:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Medical <br /> Equipment</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Management <br /> of Diagnostic <br /> Imaging <br /> Centers</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Totals</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">For the three months ended Sept. 30, 2020</font></td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%"><font style="font-size: 10pt">Net revenues from external customers</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">1,981</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">18,998</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">20,979</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Inter-segment net revenues</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">219</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">219</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">(Loss) Income from operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(561</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,711</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,150</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Depreciation and amortization</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">67</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">901</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">968</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Capital expenditures</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">20</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">415</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">435</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">&#160;For the three months ended Sept. 30, 2019</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Net revenues from external customers</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2,284</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">19,463</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">21,747</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Inter-segment net revenues</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">219</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">219</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">(Loss) Income from operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(736</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">6,222</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,486</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Depreciation and amortization</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">91</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">904</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">995</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Capital expenditures</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,601</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">848</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2,449</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">September&#160;30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">June 30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Accrued salaries, commissions and payroll taxes</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">4,755</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">4,492</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Litigation accruals</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">115</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">443</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Sales tax payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,362</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,353</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Legal and other professional fees</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">105</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">113</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Accounting fees</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">150</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">120</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Self-funded health insurance reserve</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">87</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Accrued interest and penalty</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">880</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">877</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Other</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">493</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">700</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Other Current Liabilities</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,864</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,185</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">September&#160;30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">June 30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%"><font style="font-size: 10pt">Capitalized software development costs</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">7,005</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">7,005</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Patents and copyrights</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,101</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,082</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Non-compete</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,100</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,100</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Customer relationships</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3,800</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">3,800</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross Other intangible assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">20,006</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">19,987</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Less: Accumulated amortization</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">15,970</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">15,878</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Other Intangible Assets</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,036</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,109</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">Information relating to uncompleted contracts is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">September 30,<br /> 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">June 30,<br /> &#160;2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Costs incurred on uncompleted contracts</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">448</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">448</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Estimated earnings</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">309</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">309</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Subtotal</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">757</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">757</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Less: Billings to date</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">604</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">604</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><font style="font-size: 10pt">Total Costs and estimated earnings in excess of billings on uncompleted contracts</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">153</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">153</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of September 30, 2020 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Year Ending <br /> September 30,</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Operating Lease <br /> Payments</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Financing Lease Payments</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; text-align: center"><font style="font-size: 10pt">2021</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">5,045</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">122</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,847</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">244</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,698</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">244</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">2024</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,485</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">244</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">2025</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,390</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">244</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">Thereafter</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">18,545</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">408</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">Present value discount</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(9,331</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(169</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: center"><font style="font-size: 10pt">Total lease liability</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">32,679</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,337</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s patient fee revenue, net of contractual allowances and discounts for the three months ended September 30, 2020 and 2019 are summarized in the following table.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">For the Three Months Ended <br /> September 30,</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Commercial Insurance/ Managed Care</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">946</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">1,354</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Medicare/Medicaid</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">197</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">266</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Workers&#8217; Compensation/Personal Injury</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,387</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,294</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Other</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">561</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">131</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 12.6pt; text-indent: -12.6pt"><font style="font-size: 10pt">Patient Fee Revenue, net of contractual allowances and discounts</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,091</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,045</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future revenue to be recognized over the following four years at September 30, 2020 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><font style="font-size: 10pt">2022</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 8%; text-align: right"><font style="font-size: 10pt">879</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">827</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">2024</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">827</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">2025</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">228</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,761</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Receivables, net is comprised of the following at September 30, 2020, and June 30, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">September 30, 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Gross Receivable</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Allowance for doubtful accounts</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Net</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Accounts receivable</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">4,706</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">515</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">4,191</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Accounts receivable - related party</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">102</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">102</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Medical receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,293</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,293</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Management and other fees receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">41,844</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12,833</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">29,011</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,782</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,780</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,002</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Gross Receivable</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Allowance for doubtful accounts</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Net</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Accounts receivable</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">4,828</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">515</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 8%; text-align: right"><font style="font-size: 10pt">4,313</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Accounts receivable - related party</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Notes receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,172</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,172</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Medical receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,172</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,172</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Management and other fees receivable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">38,501</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,063</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">27,438</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt"><font style="font-size: 10pt">Management and other fees receivable from related medical practices (&#8220;PC&#8217;s&#8221;)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,218</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,322</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,896</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Principles of Consolidation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the &#8220;Company&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Revenues</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and codified in the ASC as topic 606 (&#8220;ASC 606&#8221;). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company&#8217;s revenue recognition policies and significant judgments employed in the determination of revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues generally relate to net patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recent Accounting Pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-04, Intangibles &#8211; Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance will have no material impact on our Consolidated Financial Statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of September 30, 2020 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2020 or 2019, and it does not believe that any of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reclassifications&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net income for any periods presented.</p> 671000 183076000 183076000 -233000 125000 1990000 1990000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">Principles of Consolidation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the &#8220;Company&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Revenues</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and codified in the ASC as topic 606 (&#8220;ASC 606&#8221;). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company&#8217;s revenue recognition policies and significant judgments employed in the determination of revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues generally relate to net patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Earnings Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share (&#8220;EPS&#8221;) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, &#8220;Participating Securities and the Two-Class method&#8221;, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three months ended September 30, 2020 and 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three months ended September 30, 2020 and 2019, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Earnings Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three months ended <br /> September 30, 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three months ended <br /> September 30, 2019</font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Common Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Class C Common <br /> Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Common Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Class C Common <br /> Stock</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Numerator:&#160; <br /> Net income available to common stockholders</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">2,508</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">2,355</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">39</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">3,299</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">3,097</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">51</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Denominator:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Weighted average shares outstanding</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,447</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,447</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,432</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,432</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Basic income per common share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.39</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.37</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.10</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.51</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.48</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.13</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Denominator: <br /> Weighted average shares outstanding</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,447</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">383</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,432</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">383</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Convertible Class C Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">128</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8212;&#160;&#160;</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">128</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8212;&#160;&#160;</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Total Denominator for diluted earnings per share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,575</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,560</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Diluted income per common share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.36</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.10</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.47</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.13</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recent Accounting Pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-04, Intangibles &#8211; Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance will have no material impact on our Consolidated Financial Statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of September 30, 2020 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2020 or 2019, and it does not believe that any of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reclassifications&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net income for any periods presented.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: -9pt">NOTE 5 - INVENTORIES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: -9pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">Inventories included in the accompanying condensed consolidated balance sheets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2020</p></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">June 30,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2020</p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 5.4pt"><font style="font-size: 10pt">Purchased parts, components and supplies</font></td> <td style="width: 8%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,537</font></td> <td style="width: 1%">&#160;</td> <td style="width: 8%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,544</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt"><font style="font-size: 10pt">Work-in-process</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">161</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">105</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><font style="font-size: 10pt">TOTAL INVENTORIES</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,698</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,649</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">NOTE 12 - INCOME TAXES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740-270, Income Taxes &#8211; Interim Reporting, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur. For the three months ended September 30, 2020 and 2019, the Company recorded income tax expense of $849 in 2020 as compared to $1,107 in 2019. The 2020 provision is comprised of a current income tax component of $0 and a deferred income tax component of $849. Obligations for any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits and utilization of net operating loss carryforwards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC topic 740. The Company believes there are no uncertain tax positions in prior years tax filings and therefore it has not recorded a liability for unrecognized tax benefits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as &#8220;Interest expense, net&#8221;. Penalties if incurred would be recognized as a component of &#8220;Selling, general and administrative&#8221; expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded a deferred tax asset of $17,961 and a deferred tax liability of $234 as of September 30, 2020, primarily relating to net operating loss carryforwards of approximately $49,925 available to offset future taxable income through 2031. The net operating losses begin to expire in 2023 for federal tax and state income tax purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 27, 2020 Congress enacted the CARES Act (Coronavirus Aid, Relief and Economic Security Act). The Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding prior and future operation losses, temporary changes to prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property and enhanced recoverability of AMT tax credits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As we continue to monitor tax implications of the CARES Act and other state and federal stimulus tax legislation, we may make adjustments to our estimates and record additional amounts for tax assets and liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of September 30, 2020, no such changes in ownership have occurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related to research and development tax credits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Earnings Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share (&#8220;EPS&#8221;) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, &#8220;Participating Securities and the Two-Class method&#8221;, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three months ended September 30, 2020 and 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three months ended September 30, 2020 and 2019, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Earnings Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three months ended <br /> September 30, 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three months ended <br /> September 30, 2019</font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Common Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Class C Common <br /> Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Common Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Class C Common <br /> Stock</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Numerator:&#160; <br /> Net income available to common stockholders</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">2,508</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">2,355</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">39</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">3,299</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">3,097</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">51</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Denominator:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Weighted average shares outstanding</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,447</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,447</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,432</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,432</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Basic income per common share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.39</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.37</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.10</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.51</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.48</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.13</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Denominator: <br /> Weighted average shares outstanding</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,447</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">383</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,432</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">383</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Convertible Class C Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">128</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8212;&#160;&#160;</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">128</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8212;&#160;&#160;</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Total Denominator for diluted earnings per share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,575</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,560</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Diluted income per common share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.36</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.10</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.47</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.13</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Earnings Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three months ended <br /> September 30, 2020</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three months ended <br /> September 30, 2019</font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Common Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Class C Common <br /> Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Common Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Class C Common <br /> Stock</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Numerator:&#160; <br /> Net income available to common stockholders</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">2,508</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">2,355</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">39</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">3,299</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">3,097</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right"><font style="font-size: 10pt">51</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Denominator:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Weighted average shares outstanding</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,447</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,447</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,432</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,432</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Basic income per common share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.39</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.37</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.10</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.51</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.48</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.13</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Denominator: <br /> Weighted average shares outstanding</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,447</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">383</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,432</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">383</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Convertible Class C Stock</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">128</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8212;&#160;&#160;</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">128</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8212;&#160;&#160;</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Total Denominator for diluted earnings per share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,575</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,560</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt"><font style="font-size: 10pt">Diluted income per common share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.36</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.10</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.47</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.13</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">Inventories included in the accompanying condensed consolidated balance sheets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2020</p></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">June 30,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2020</p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 5.4pt"><font style="font-size: 10pt">Purchased parts, components and supplies</font></td> <td style="width: 8%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,537</font></td> <td style="width: 1%">&#160;</td> <td style="width: 8%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,544</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt"><font style="font-size: 10pt">Work-in-process</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">161</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">105</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><font style="font-size: 10pt">TOTAL INVENTORIES</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,698</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,649</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> .242 .458 .3 EX-101.CAL 6 fonr-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 fonr-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 fonr-20200930_lab.xml XBRL LABEL FILE Equity Components [Axis] Accumulated Deficit Class of Stock [Axis] Common Stock Class C Common Stock Statement, Operating Activities Segment [Axis] Medical Equipment Management Of Diagnostic Imaging Centers Class A Non-Voting Preferred Stock Class B Common Stock AccountsNotesLoansAndFinancingReceivableByReceivableType [Axis] Gross Receivable Allowance for Doubtful Accounts Finite-Lived Intangible Assets by Major Class [Axis] Capitalized software development costs Patents and copyrights Non-compete Customer relationships Health Care Organization, Revenue Sources [Axis] Workers Compensation/Personal Injury Medicare/Medicaid Commercial Insurance / Managed Care Other Preferred Stock Paid in capital in excess of par value Treasury Stock Noncontrolling Interest Ownership [Axis] Health Diagnostics Management LLC (HDM) Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Document Fiscal Year Focus Current Fiscal Year End Date Document Fiscal Period Focus Amendment Flag Entity File Number Entity Incorporation State Country Code Is Entity Interactive Data Current Is Entity's Reporting Status Current? Is Entity a Small Business Entity Filer Category Is Entity an Emerging Growth Company Entity Common Stock, Shares Outstanding Trading Symbol Security Exchange Name Security 12B Title Entity Shell Company ASSETS Current Assets: Cash and cash equivalents Short term investments Accounts receivable - net Account receivable - related parties Medical receivables -net Management and other fees receivable -net Management and other fees receivable - related medical practices -net Inventories Costs and estimated earnings in excess of billings on uncompleted contracts Income taxes receivable Prepaid expenses and other current assets Total Current Assets Accounts receivable - long term Deferred income tax asset Property and equipment - net Right-of-use Asset - operating lease Right-of-use-asset - financing lease Goodwill Other intangible assets - net Other assets Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Current portion of long-term debt and capital leases Accounts payable Other current liabilities Unearned revenue on service contracts Unearned revenue on service contracts - related parties Operating lease liability - current portion Financing lease liability - current portion Customer deposits Total Current Liabilities Long-Term Liabilities: Unearned revenue on service contracts Deferred Income Tax Liability Due to related party medical practices Operating lease liability - net of current portion Financing lease liability - net of current portion Long-term debt and capital leases, less current portion Other liabilities Total Long-Term Liabilities Total Liabilities STOCKHOLDERS' EQUITY: Preferred stock value Common stock value Paid-in capital in excess of par value Accumulated deficit Treasury stock, at cost Total Fonar Corporation Stockholder Equity Noncontrolling interests Total Stockholders' Equity Total Liabilities and Stockholders' Equity Preferred Stock, Par Value Preferred Stock, Authorized Preferred Stock, Issued Preferred Stock, Outstanding Common Stock, Par Value Common Stock, Authorized Common Stock, Issued Common Stock, Outstanding REVENUES Patient fee revenue, net of contractual allowances and discounts Product sales - net Service and repair fees - net Service and repair fees - related parties - net Management and other fees - net Management and other fees - related medical practices - net Total Revenues - net COSTS AND EXPENSES Costs related to patient fee revenue Costs related to product sales Costs related to service and repair fees Costs related to service and repair fees - related parties Costs related to management and other fees Costs related to management and other fees - related medical practices Research and development Selling, general and administrative Total Costs and Expenses INCOME Income From Operations Other Income Interest Expense Investment Income Income Before Provision for Income Taxes and Noncontrolling Interests Provision for Income Taxes Net Income Net Income - Noncontrolling Interests Net Income - Attributable to FONAR Basic Net Income Per Share Diluted Net Income Per Share Basic and Diluted Income Per Share Weighted Average Basic Shares Outstanding Weighted Average Diluted Shares Outstanding Weighted Average Basic and Diluted Shares Outstanding Balance - Beginning, Value Issuance of common stock (value) Net Income Distributions - noncontrolling Income - Noncontrolling interests Balance - Ending, Value Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization Amortization on right-of-use assets Provision (Recovery) for bad debts Stock issued for costs and expense Deferred income tax - net Abandoned patents (Increase) decrease in operating assets, net: Accounts, medical and management fee receivable(s) Notes receivable Costs and estimated earnings in excess of billings on uncompleted contracts Inventories Income tax receivable Prepaid expenses and other current assets Other assets Increase (decrease) in operating liabilities, net: Accounts payable Other current liabilities Operating lease liabilities Financing lease liability Customer advances Other liabilities Net cash provided by operating activities Cash Flows from Investing Activities: Purchases of property and equipment Purchase of short term investment Cost of patents Net cash used in investing activities Cash Flows from Financing Activities: Repayment of borrowings and capital lease obligations Proceeds from debt Distributions to noncontrolling interests Net cash used in financing activities Net Increase (decrease) in Cash and Cash Equivalents Cash and Cash Equivalents - Beginning of Period Cash and Cash Equivalents - End of Period Accounting Policies [Abstract] NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Receivables [Abstract] NOTE 3 - ACCOUNTS RECEIVABLE. MEDICAL RECEIVABLES AND MANAGEMENT AND OTHER FEES RECEIVABLE (USD $) Leases [Abstract] NOTE 4 - OPERATING & FINANCING LEASES Inventory Disclosure [Abstract] NOTE 5 - INVENTORIES Notes to Financial Statements NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS Goodwill and Intangible Assets Disclosure [Abstract] NOTE 7 - OTHER INTANGIBLE ASSETS Other Liabilities, Current [Abstract] NOTE 8 - OTHER CURRENT LIABILITIES Segment Reporting [Abstract] NOTE 9 - SEGMENT AND RELATED INFORMATION Supplemental Cash Flow Elements [Abstract] NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION Commitments and Contingencies Disclosure [Abstract] NOTE 11 - COMMITMENTS AND CONTINGENCIES Income Tax Disclosure [Abstract] NOTE 12 - INCOME TAXES Subsequent Events [Abstract] NOTE 13 - SUBSEQUENT EVENTS Principles of Consolidation Revenue Earnings Per Share Recent Accounting Pronouncements Reclassifications Earnings Per Share Summary of Allowance For Doubtful Accounts Receivables - Non Current - net Patient fee revenue - net Lease, Liability, Maturity Inventories Information relating to uncompleted contracts Other intangible assets - net Other current liabilities Segment information Related Party [Axis] The ownership interest of Imperial Management Services after reorganization of newly expanded HDM (percent). The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM (percent). The ownership interest of the original investors of HDM after reorganization of newly expanded HDM (percent). Basic Numerator: Net income available to common stockholders Basic Denominator: Weighted average shares outstanding Basic income per common share Shares included upon conversion of Class C Common to calculate a diluted EPS Total Denominator for diluted earnings per share Diluted income per common share Shares included upon conversion of Class C Common to calculate a diluted EPS. Receivable Type [Axis] Accounts receivable Accounts receivable - Related party Medical Receivables Notes receivable Management and other fees receivable Management and other fees receivable from related medical practices ("PC's") Receivables, Long-term Contracts or Programs [Abstract] 2022 2023 2024 2025 Total Note 3 - Accounts Receivable Medical Receivable And Management And Other Fees Receivable - Percentage of PC's net revenue derived from no-fault and personal injury protection claims Percentage of consolidated net revenue from management fees charged to related party medical practices Operating Lease 2021 2022 2023 2024 2025 Thereafter Present Value discount Total lease liability Financing Lease 2021 2022 2023 2024 2025 Thereafter Present Value discount, Financing Lease Total lease liability Receivable from landlord for tenant improvements Operating lease payments Purchased parts, components and supplies Work-in-process Total inventories Costs incurred on uncompleted contracts Estimated earnings Costs and estimated earnings on uncompleted contracts Less: Billings to date Total costs and estimated earnings in excess of billings on uncompleted contracts Gross other intangible assets Less: Accumulated amortization Other intangible assets-net Amortization of intangible assets Accrued salaries, commissions and payroll taxes Litigation accruals Sales tax payable Legal and other professional fees Accounting fees Self-funded health insurance reserve Accrued interest and penalty Other Other current liabilities Operating Activities [Axis] Net revenues from external customers Inter-segment net revenues (Loss) Income from operations Depreciation and amortization Capital expenditures Interest paid Income taxes paid Recorded tax obligations Tax interest and penalties Maximum limit for individual claims under stop-loss umbrella policy for health insurance Litigation settelement description Income tax expense Income tax component - current Income tax component - deferred Deferred tax assets Deferred tax liability Net operating loss (NOL) carryforwards available to offset future taxable income Reimbursement of alternative minimum tax credits description Accounts receivable from service and repair fees of Related MRI scanner customers; net of allowances for doubtful accounts. Accounts receivable - net - non current - from service and repair fees of non related MRI scanner customers; net of allowances for doubtful accounts. Accounts receivable from service and repair fees of Related Party MRI scanner customers; net of allowances for doubtful accounts Accounts receivable - net - Current from service and repair fees of Non Related MRI scanner customers; net of allowances for doubtful accounts. Amount within current period that has been billed to customer. Class A NonVoting Preferred Stock Commercial Insurance Managed Care Member Costs and estimated earnings on uncompleted contracts. Costs And EstimatedEarningsOn Uncompleted Contracts And Customer Advances Costs related to management and other fees - non related medical practices. Costs related to management and other fees - related medical practices. Costs related to Product sales-net revenue for MRI scanners, upgrades and supplies. Costs incurred and are to service and repair costs related to the general maintenance of the Company's MRI installation base. This includes the costs of maintenance on client contracts - for non-related parties. Costs incurred and are to service and repair costs related to the general maintenance of the Company's MRI installation base. This includes the costs of maintenance on client contracts - for related parties. Table of total customer advances Estimated Earnings on uncompleted contracts. Management and other fees receivable from MRI Centers owned by non-related parties - net of allowances for doubtful accounts. Management and other fees are revenues attributable to the Company's physician and diagnostic services management segment, HMCA. These revenues, from non-related professional corporations, substantially consist of fees from management agreements. Payment of the fees is dependent on collection by the PCs of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations. Management and other fees are revenues attributable to the Company's physician and diagnostic services management segment, HMCA. These revenues, from the related professional corporations, substantially consist of fees from management agreements. Payment of the fees is dependent on collection by the PCs of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations. Management of Diagnostic Imaging Centers - Member - Custom element Management of, and other fees receivable from MRI Centers owned by related parties - net of allowances for doubtful accounts. The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $100,000 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. Medical equipment - Member - Custom element Medical receivable from management of specific centers - net of allowances for doubtful accounts. Medicare Medicaid Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances. Other Revenue Source Patents and copyrights - Member - Custom elements Revenue derived from the sale of Fonar MRI scanners or upgrades. Provision for bad debts used for calculationof cash flow statements. Revenue derived from maintenance services provided under contracts or arrangements with non related parties. Revenue derived from maintenance services provided under contracts or arrangements with clients for related parties - net Amount of receivable reflecting the cost incurred on uncompleted contracts in excess of related billings, net of current billings in excess of costs and estimated earnings on uncompleted contracts The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. For related parties. Workers Compensation Personal Injury Percentage of PCs net revenue derived from nofault and personal injury protection claims. Percentage of consolidated net revenue from management fees. HDM Member Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name Health Management Company of America. Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name Health Management Company of America. Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name Health Management Company of America. Assets, Current Net Assets Liabilities, Current Deferred Revenue, Noncurrent Liabilities, Noncurrent Liabilities Treasury Stock, Value Stockholders' Equity Attributable to Parent Liabilities and Equity Revenues, Net of Interest Expense Costs and Expenses Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net Interest Expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Payments of Ordinary Dividends, Noncontrolling Interest Increase (Decrease) in Accounts Receivable Increase (Decrease) in Receivables Increase (Decrease) in Unbilled Receivables Increase (Decrease) in Inventories Increase (Decrease) in Income Taxes Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Other Noncurrent Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Current Liabilities Increase (Decrease) in Other Noncurrent Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Short-term Investments Payments to Acquire Intangible Assets Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash and Cash Equivalents, at Carrying Value Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Inventory, Current [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Construction Contractor, Receivable, Excluding Contract Retainage Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Five PresentValueDiscount Operating Lease, Liability Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year Two Finance Lease, Liability, to be Paid, Year Three Finance Lease, Liability, to be Paid, Year Four Finance Lease, Liability, to be Paid, Year Five Finance Lease, Liability, to be Paid, after Year Five PresentValueDiscountFinancingLease Finance Lease, Liability, Payment, Due Management and other fees - related medical practices - net [Default Label] Less: Billings to date TotalCostsAndEstimatedEarningsInExcessOfBillingsOnUncompletedContractsNet Other Sundry Liabilities, Current Depreciation, Depletion and Amortization EX-101.PRE 9 fonr-20200930_pre.xml XBRL PRESENTATION FILE EX-101.SCH 10 fonr-20200930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTE 5 - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - NOTE 9 - SEGMENT AND RELATED INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - NOTE 11 - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - NOTE 12 - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - NOTE 13 - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - NOTE 5 - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - NOTE 9 - SEGMENT AND RELATED INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE & MANAGEMENT & OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - NOTE 5 - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - NOTE 9 - SEGMENT AND RELATED INFORMATION - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION ($) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - NOTE 12 - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
3 Months Ended
Sep. 30, 2020
Nov. 06, 2020
Entity Registrant Name FONAR CORP  
Entity Central Index Key 0000355019  
Document Type 10-Q  
Document Period End Date Sep. 30, 2020  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --06-30  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity File Number 0-10248  
Entity Incorporation State Country Code DE  
Is Entity Interactive Data Current Yes  
Is Entity's Reporting Status Current? Yes  
Is Entity a Small Business true  
Entity Filer Category Non-accelerated Filer  
Is Entity an Emerging Growth Company false  
Trading Symbol FONR  
Security Exchange Name NASDAQ  
Security 12B Title Common Stock  
Entity Shell Company false  
Common Stock    
Entity Common Stock, Shares Outstanding   6,447,463
Class B Common Stock    
Entity Common Stock, Shares Outstanding   146
Class C Common Stock    
Entity Common Stock, Shares Outstanding   382,513
Class A Non-Voting Preferred Stock    
Entity Common Stock, Shares Outstanding   313,438
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 30, 2020
Jun. 30, 2020
Current Assets:    
Cash and cash equivalents $ 38,763 $ 36,802
Short term investments 32 32
Accounts receivable - net 4,191 4,313
Account receivable - related parties 102 6
Medical receivables -net 16,293 16,172
Management and other fees receivable -net 29,011 27,438
Management and other fees receivable - related medical practices -net 7,002 6,896
Inventories 1,698 1,649
Costs and estimated earnings in excess of billings on uncompleted contracts 153 153
Income taxes receivable 671
Prepaid expenses and other current assets 1,879 1,758
Total Current Assets 99,124 95,890
Accounts receivable - long term 2,839 2,730
Deferred income tax asset 17,961 18,810
Property and equipment - net 20,904 21,364
Right-of-use Asset - operating lease 30,489 31,392
Right-of-use-asset - financing lease 1,276 1,326
Goodwill 3,985 3,985
Other intangible assets - net 4,036 4,109
Other assets 642 653
Total Assets 181,256 180,259
Current Liabilities:    
Current portion of long-term debt and capital leases 169 108
Accounts payable 1,848 1,965
Other current liabilities 7,864 8,185
Unearned revenue on service contracts 4,203 4,105
Unearned revenue on service contracts - related parties 83
Operating lease liability - current portion 3,433 3,370
Financing lease liability - current portion 136 75
Customer deposits 912 855
Total Current Liabilities 18,648 18,663
Long-Term Liabilities:    
Unearned revenue on service contracts 2,761 2,656
Deferred Income Tax Liability 234 234
Due to related party medical practices 93 93
Operating lease liability - net of current portion 29,246 30,105
Financing lease liability - net of current portion 1,201 1,251
Long-term debt and capital leases, less current portion 859 865
Other liabilities 161 150
Total Long-Term Liabilities 34,555 35,354
Total Liabilities 53,203 54,017
STOCKHOLDERS' EQUITY:    
Paid-in capital in excess of par value 183,076 183,076
Accumulated deficit (53,707) (56,215)
Treasury stock, at cost (675) (675)
Total Fonar Corporation Stockholder Equity 128,695 126,187
Noncontrolling interests (642) 55
Total Stockholders' Equity 128,053 126,242
Total Liabilities and Stockholders' Equity 181,256 180,259
Class A Non-Voting Preferred Stock    
STOCKHOLDERS' EQUITY:    
Preferred stock value
Preferred Stock    
STOCKHOLDERS' EQUITY:    
Preferred stock value
Common Stock    
STOCKHOLDERS' EQUITY:    
Common stock value 1 1
Class B Common Stock    
STOCKHOLDERS' EQUITY:    
Common stock value
Class C Common Stock    
STOCKHOLDERS' EQUITY:    
Common stock value
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
Sep. 30, 2020
Jun. 30, 2020
Class A Non-Voting Preferred Stock    
Preferred Stock, Par Value $ 0.0001 $ 0.0001
Preferred Stock, Authorized 453,000 453,000
Preferred Stock, Issued 313,000 313,000
Preferred Stock, Outstanding 313,000 313,000
Preferred Stock    
Preferred Stock, Par Value $ 0.001 $ 0.001
Preferred Stock, Authorized 567,000 567,000
Preferred Stock, Issued
Preferred Stock, Outstanding
Common Stock    
Common Stock, Par Value $ 0.0001 $ 0.0001
Common Stock, Authorized 8,500,000 8,500,000
Common Stock, Issued 6,459,000 6,459,000
Common Stock, Outstanding 6,447,000 6,447,000
Class B Common Stock    
Common Stock, Par Value $ 0.0001 $ 0.0001
Common Stock, Authorized 227,000 227,000
Common Stock, Issued 146 146
Common Stock, Outstanding 146 146
Class C Common Stock    
Common Stock, Par Value $ 0.0001 $ 0.0001
Common Stock, Authorized 567,000 567,000
Common Stock, Issued 383,000 383,000
Common Stock, Outstanding 383,000 383,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
REVENUES    
Patient fee revenue, net of contractual allowances and discounts $ 5,091 $ 6,045
Product sales - net 28 192
Service and repair fees - net 1,925 2,064
Service and repair fees - related parties - net 28 28
Management and other fees - net 11,214 11,028
Management and other fees - related medical practices - net 2,693 2,390
Total Revenues - net 20,979 21,747
COSTS AND EXPENSES    
Costs related to patient fee revenue 2,521 2,863
Costs related to product sales 132 330
Costs related to service and repair fees 626 750
Costs related to service and repair fees - related parties 9 10
Costs related to management and other fees 5,550 6,005
Costs related to management and other fees - related medical practices 1,428 1,537
Research and development 400 472
Selling, general and administrative 6,163 4,294
Total Costs and Expenses 16,829 16,261
INCOME    
Income From Operations 4,150 5,486
Other Income (140)
Interest Expense (22) (21)
Investment Income 112 148
Income Before Provision for Income Taxes and Noncontrolling Interests 4,100 5,613
Provision for Income Taxes (849) (1,107)
Net Income 3,251 4,506
Net Income - Noncontrolling Interests (743) (1,207)
Net Income - Attributable to FONAR $ 2,508 $ 3,299
Basic Net Income Per Share $ 0.39 $ 0.51
Weighted Average Basic Shares Outstanding 6,447 6,432
Common Stock    
INCOME    
Net Income - Attributable to FONAR $ 2,355 $ 3,097
Basic Net Income Per Share $ 0.37 $ 0.48
Diluted Net Income Per Share $ 0.36 $ 0.47
Weighted Average Basic Shares Outstanding 6,447 6,432
Weighted Average Diluted Shares Outstanding 6,575 6,560
Class A Non-Voting Preferred Stock    
INCOME    
Net Income - Attributable to FONAR $ 114 $ 151
Class C Common Stock    
INCOME    
Net Income - Attributable to FONAR $ 39 $ 51
Basic Net Income Per Share $ 0.10 $ 0.13
Diluted Net Income Per Share 0.10 0.13
Basic and Diluted Income Per Share $ 0.10 $ 0.13
Weighted Average Basic Shares Outstanding 383 383
Weighted Average Diluted Shares Outstanding 383 383
Weighted Average Basic and Diluted Shares Outstanding 383 383
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Common Stock
Paid in capital in excess of par value
Accumulated Deficit
Treasury Stock
Noncontrolling Interest
Total
Balance - Beginning, Value at Jun. 30, 2019 $ 1 $ 181,086 $ (64,456) $ (675) $ 2,156 $ 118,112
Issuance of common stock (value) 1,990 1,990
Net Income 3,299 3,299
Distributions - noncontrolling (1,755) (1,755)
Income - Noncontrolling interests 1,207 1,207
Balance - Ending, Value at Sep. 30, 2019 1 183,076 (61,157) (675) 1,608 122,854
Balance - Beginning, Value at Jun. 30, 2020 1 183,076 (56,215) (675) 55 126,242
Issuance of common stock (value)
Net Income 2,508 2,508
Distributions - noncontrolling (1,440) (1,440)
Income - Noncontrolling interests 743 743
Balance - Ending, Value at Sep. 30, 2020 $ 1 $ 183,076 $ (53,707) $ (675) $ (642) $ 128,053
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash Flows from Operating Activities:    
Net income $ 3,251 $ 4,506
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 968 995
Amortization on right-of-use assets 953 819
Provision (Recovery) for bad debts 2,227 (239)
Stock issued for costs and expense 1,991
Deferred income tax - net 849 1,004
Abandoned patents 1
(Increase) decrease in operating assets, net:    
Accounts, medical and management fee receivable(s) (4,109) (1,188)
Notes receivable 14
Costs and estimated earnings in excess of billings on uncompleted contracts 218
Inventories (49) 7
Income tax receivable 671
Prepaid expenses and other current assets (125) 233
Other assets (44)
Increase (decrease) in operating liabilities, net:    
Accounts payable (117) (345)
Other current liabilities (36) (2,889)
Operating lease liabilities (796) (750)
Financing lease liability 12
Customer advances 58 (62)
Other liabilities 10 (13)
Net cash provided by operating activities 3,782 4,243
Cash Flows from Investing Activities:    
Purchases of property and equipment (415) (2,411)
Purchase of short term investment (119)
Cost of patents (20) (38)
Net cash used in investing activities (435) (2,568)
Cash Flows from Financing Activities:    
Repayment of borrowings and capital lease obligations (9) (8)
Proceeds from debt 63
Distributions to noncontrolling interests (1,440) (1,755)
Net cash used in financing activities (1,386) (1,763)
Net Increase (decrease) in Cash and Cash Equivalents 1,961 (88)
Cash and Cash Equivalents - Beginning of Period 36,802 13,882
Cash and Cash Equivalents - End of Period $ 38,763 $ 13,794
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
3 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Description of Business

 

Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name “Health Management Company of America”.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K filed on October 1, 2020 for the fiscal year ended June 30, 2020.

 

During March 2020 the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and economies which has adversely effected our workforce, liquidity, financial conditions, revenues, profitability and business operations. Generally COVID-19 had caused us to require that much of our workforce work from home and has restricted the ability of our personnel to travel for marketing purposes or to service our customers. The Company experienced a sudden drop in scan volume for a short term period and while the Company is not back to pre-COVID-19 levels, the volume has risen. At the end of fiscal year ending June 30, 2020, the Company was able to enact certain decisions to allow the Company to survive during the global pandemic and from further losses or additional decreases in scan volume. The Company immediately enacted wide scale furloughs, deferment of up to 50% of management salaries, halted variable compensation plans and rent deferrals we negotiated with the majority of all landlords. The Company also received some government stimulus funds from the Paycheck Protection Program (“PPP”) and Medicare advances/stimulus payments. Although we are unable to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19, the Company believes with positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Revenues

On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.

 

Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

 

Earnings Per Share

 

Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three months ended September 30, 2020 and 2019.

 

Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three months ended September 30, 2020 and 2019, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.

 

Earnings Per Share

 

    Three months ended
September 30, 2020
  Three months ended
September 30, 2019
    Total   Common Stock   Class C Common
Stock
  Total   Common Stock   Class C Common
Stock
Basic                        
Numerator: 
Net income available to common stockholders
  $ 2,508     $ 2,355     $ 39     $ 3,299     $ 3,097     $ 51  
Denominator:                                                
Weighted average shares outstanding     6,447       6,447       383       6,432       6,432       383  
Basic income per common share   $ 0.39     $ 0.37     $ 0.10     $ 0.51     $ 0.48     $ 0.13  
Diluted                                                
Denominator:
Weighted average shares outstanding
            6,447       383               6,432       383  
Convertible Class C Stock             128       —                 128       —    
Total Denominator for diluted earnings per share             6,575       383               6,560       383  
Diluted income per common share           $ 0.36     $ 0.10             $ 0.47     $ 0.13  

 

Recent Accounting Pronouncements

  

In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance will have no material impact on our Consolidated Financial Statements.

 

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of September 30, 2020 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2020 or 2019, and it does not believe that any of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.

 

Reclassifications 

Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net income for any periods presented. 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE
3 Months Ended
Sep. 30, 2020
Receivables [Abstract]  
NOTE 3 - ACCOUNTS RECEIVABLE. MEDICAL RECEIVABLES AND MANAGEMENT AND OTHER FEES RECEIVABLE (USD $)

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE

 

Receivables, net is comprised of the following at September 30, 2020, and June 30, 2020:

 

    September 30, 2020  
    Gross Receivable     Allowance for doubtful accounts     Net  
Accounts receivable   $ 4,706     $ 515     $ 4,191  
Accounts receivable - related party   $ 102           $ 102  
Medical receivable   $ 16,293     $     $ 16,293  
Management and other fees receivable   $ 41,844     $ 12,833     $ 29,011  
Management and other fees receivable from related medical practices (“PC’s”)   $ 10,782     $ 3,780     $ 7,002  

 

    June 30, 2020  
    Gross Receivable     Allowance for doubtful accounts     Net  
Accounts receivable   $ 4,828     $ 515     $ 4,313  
Accounts receivable - related party   $ 6           $ 6  
Notes receivable   $ 16,172     $     $ 16,172  
Medical receivable   $ 16,172     $     $ 16,172  
Management and other fees receivable   $ 38,501     $ 11,063     $ 27,438  
Management and other fees receivable from related medical practices (“PC’s”)   $ 10,218     $ 3,322     $ 6,896  

 

The Company’s customers are concentrated in the healthcare industry.

 

Accounts Receivable

 

Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided.

 

Long Term Accounts Receivable

 

The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be recognized over the following four years at September 30, 2020 are as follows:

 

2022   $ 879  
2023     827  
2024     827  
2025     228  
Total   $ 2,761  

 

Medical Receivables

 

Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that will not be collected. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site.

 

Management and Other Fees Receivable

 

The Company’s receivables from the related and non-related professional corporations (PC’s) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PC’s of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations.

 

Payment of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 66% and 67% of the PCs’ net revenues for the three months ended September 30, 2020 and 2019, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically been within management’s expectations.

 

Net revenues from management and other fees charged to the related PCs accounted for approximately 12.8% and 11.0% of the consolidated net revenues for the three months ended September 30, 2020 and 2019, respectively.

 

Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company.

 

The Company’s patient fee revenue, net of contractual allowances and discounts for the three months ended September 30, 2020 and 2019 are summarized in the following table.

 

    For the Three Months Ended
September 30,
 
    2020     2019  
Commercial Insurance/ Managed Care   $ 946     $ 1,354  
Medicare/Medicaid     197       266  
Workers’ Compensation/Personal Injury     3,387       4,294  
Other     561       131  
Patient Fee Revenue, net of contractual allowances and discounts   $ 5,091     $ 6,045  
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 4 - OPERATING & FINANCING LEASES
3 Months Ended
Sep. 30, 2020
Leases [Abstract]  
NOTE 4 - OPERATING & FINANCING LEASES

NOTE 4 – OPERATING & FINANCING LEASES

 

During February 2016, FAS issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Lease with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard was effective for us beginning July 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We have also elected the transition package of the practical expedients permitted within the standard which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and indirect costs. The adoption of this guidance had a material impact on the Company’s balance sheet by virtue of including the present value of its future operating lease payments as a liability of $33.3 million and related right-to-use lease assets as of July 1, 2019. At the time of adoption of this guidance we had no significant financing leases.

 

The Company accounts for its various operating leases in accordance with Accounting Standards Codification (‘ASC’) 842 – Lease, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Also included in other current assets is a $202,268 receivable from a landlord for tenant improvements. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company.

 

A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of September 30, 2020 is as follows:

 

Year Ending
September 30,
  Operating Lease
Payments
    Financing Lease Payments  
2021   $ 5,045     $ 122  
2022     4,847       244  
2023     4,698       244  
2024     4,485       244  
2025     4,390       244  
Thereafter     18,545       408  
Present value discount     (9,331 )     (169 )
Total lease liability   $ 32,679     $ 1,337  
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 5 - INVENTORIES
3 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
NOTE 5 - INVENTORIES

NOTE 5 - INVENTORIES

 

Inventories included in the accompanying condensed consolidated balance sheets consist of the following:

 

   

September 30,

2020

 

June 30,

2020

Purchased parts, components and supplies   $ 1,537     $ 1,544  
Work-in-process     161       105  
TOTAL INVENTORIES   $ 1,698     $ 1,649  
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS
3 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS

NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS

 

Information relating to uncompleted contracts is as follows:

 

    September 30,
2020
    June 30,
 2020
 
Costs incurred on uncompleted contracts   $ 448     $ 448  
Estimated earnings     309       309  
Subtotal     757       757  
Less: Billings to date     604       604  
Total Costs and estimated earnings in excess of billings on uncompleted contracts   $ 153     $ 153  
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 7 - OTHER INTANGIBLE ASSETS
3 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
NOTE 7 - OTHER INTANGIBLE ASSETS

NOTE 7 – OTHER INTANGIBLE ASSETS

 

Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:

 

    September 30,
2020
    June 30,
2020
 
Capitalized software development costs   $ 7,005     $ 7,005  
Patents and copyrights     5,101       5,082  
Non-compete     4,100       4,100  
Customer relationships     3,800       3,800  
Gross Other intangible assets     20,006       19,987  
Less: Accumulated amortization     15,970       15,878  
Other Intangible Assets   $ 4,036     $ 4,109  

  

Amortization of patents and copyrights for the three months ended September 30, 2020 and 2019 amounted to $45 and $47, respectively.

 

Amortization of non-compete for the three months ended September 30, 2020 and 2019 amounted to $0 and $146, respectively.

 

Amortization of customer relationships for the three months ended September 30, 2020 and 2019 amounted to $48 and $48, respectively.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 8 - OTHER CURRENT LIABILITIES
3 Months Ended
Sep. 30, 2020
Other Liabilities, Current [Abstract]  
NOTE 8 - OTHER CURRENT LIABILITIES

NOTE 8 – OTHER CURRENT LIABILITIES

 

Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:

 

    September 30,
2020
    June 30,
2020
 
Accrued salaries, commissions and payroll taxes   $ 4,755     $ 4,492  
Litigation accruals     115       443  
Sales tax payable     1,362       1,353  
Legal and other professional fees     105       113  
Accounting fees     150       120  
Self-funded health insurance reserve     4       87  
Accrued interest and penalty     880       877  
Other     493       700  
Other Current Liabilities   $ 7,864     $ 8,185  
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 9 - SEGMENT AND RELATED INFORMATION
3 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
NOTE 9 - SEGMENT AND RELATED INFORMATION

NOTE 9 - SEGMENT AND RELATED INFORMATION

 

The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers.

 

The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2020. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.

 

Summarized financial information concerning the Company’s reportable segments is shown in the following table:

 

    Medical
Equipment
    Management
of Diagnostic
Imaging
Centers
    Totals  
For the three months ended Sept. 30, 2020                  
Net revenues from external customers   $ 1,981     $ 18,998     $ 20,979  
Inter-segment net revenues   $ 219     $     $ 219  
(Loss) Income from operations   $ (561 )   $ 4,711     $ 4,150  
Depreciation and amortization   $ 67     $ 901     $ 968  
Capital expenditures   $ 20     $ 415     $ 435  
                         
 For the three months ended Sept. 30, 2019                        
Net revenues from external customers   $ 2,284     $ 19,463     $ 21,747  
Inter-segment net revenues   $ 219     $     $ 219  
(Loss) Income from operations   $ (736 )   $ 6,222     $ 5,486  
Depreciation and amortization   $ 91     $ 904     $ 995  
Capital expenditures   $ 1,601     $ 848     $ 2,449  
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION
3 Months Ended
Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]  
NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION

NOTE 10 – SUPPLEMENTAL CASH FLOW INFORMATION

 

During the three months ended September 30, 2020 and September 30, 2019, the Company paid $19 and $8 for interest, respectively.

 

During the three months ended September 30, 2020 and September 30, 2019, the Company paid $145 and $228 for income taxes, respectively.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 11 - COMMITMENTS AND CONTINGENCIES
3 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
NOTE 11 - COMMITMENTS AND CONTINGENCIES

NOTE 11 – COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company.

 

There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2020.

 

Other Matters

 

In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company’s insurance in September 2020. The Company paid the remaining balance of $315 in September 2020.

 

The Company is also delinquent in filing sales tax returns for certain states, for which the Company has transacted business. As of September 30, 2020, the Company has recorded tax obligations of approximately $1,362 plus interest and penalties of approximately $835. The Company is in the process of determining the regulatory requirements in order to become compliant.

 

The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $110 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of September 30, 2020 and June 30, 2020, the Company had approximately $4 and $87, respectively, in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the condensed consolidated balance sheets.

 

The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report. 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 12 - INCOME TAXES
3 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
NOTE 12 - INCOME TAXES

NOTE 12 - INCOME TAXES

 

In accordance with ASC 740-270, Income Taxes – Interim Reporting, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur. For the three months ended September 30, 2020 and 2019, the Company recorded income tax expense of $849 in 2020 as compared to $1,107 in 2019. The 2020 provision is comprised of a current income tax component of $0 and a deferred income tax component of $849. Obligations for any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits and utilization of net operating loss carryforwards.

 

ASC topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC topic 740. The Company believes there are no uncertain tax positions in prior years tax filings and therefore it has not recorded a liability for unrecognized tax benefits.

 

In accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net”. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses.

 

The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2016.

 

The Company recorded a deferred tax asset of $17,961 and a deferred tax liability of $234 as of September 30, 2020, primarily relating to net operating loss carryforwards of approximately $49,925 available to offset future taxable income through 2031. The net operating losses begin to expire in 2023 for federal tax and state income tax purposes.

 

On March 27, 2020 Congress enacted the CARES Act (Coronavirus Aid, Relief and Economic Security Act). The Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding prior and future operation losses, temporary changes to prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property and enhanced recoverability of AMT tax credits.

 

At the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.

 

As we continue to monitor tax implications of the CARES Act and other state and federal stimulus tax legislation, we may make adjustments to our estimates and record additional amounts for tax assets and liabilities.

 

Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of September 30, 2020, no such changes in ownership have occurred.

 

The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related to research and development tax credits.

 

A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 13 - SUBSEQUENT EVENTS
3 Months Ended
Sep. 30, 2020
Subsequent Events [Abstract]  
NOTE 13 - SUBSEQUENT EVENTS

NOTE 13 – SUBSEQUENT EVENTS

 

The Company has evaluated events that occurred subsequent to September 30, 2020 and through the date the condensed consolidated financial statements were issued.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

Revenue

Revenues

 

On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.

 

Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

Earnings Per Share

Earnings Per Share

 

Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three months ended September 30, 2020 and 2019.

 

Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three months ended September 30, 2020 and 2019, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.

 

Earnings Per Share

 

    Three months ended
September 30, 2020
  Three months ended
September 30, 2019
    Total   Common Stock   Class C Common
Stock
  Total   Common Stock   Class C Common
Stock
Basic                        
Numerator: 
Net income available to common stockholders
  $ 2,508     $ 2,355     $ 39     $ 3,299     $ 3,097     $ 51  
Denominator:                                                
Weighted average shares outstanding     6,447       6,447       383       6,432       6,432       383  
Basic income per common share   $ 0.39     $ 0.37     $ 0.10     $ 0.51     $ 0.48     $ 0.13  
Diluted                                                
Denominator:
Weighted average shares outstanding
            6,447       383               6,432       383  
Convertible Class C Stock             128       —                 128       —    
Total Denominator for diluted earnings per share             6,575       383               6,560       383  
Diluted income per common share           $ 0.36     $ 0.10             $ 0.47     $ 0.13  
Recent Accounting Pronouncements

Recent Accounting Pronouncements

  

In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance will have no material impact on our Consolidated Financial Statements.

 

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of September 30, 2020 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2020 or 2019, and it does not believe that any of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.

Reclassifications

Reclassifications 

 

Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net income for any periods presented.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Earnings Per Share

Earnings Per Share

 

    Three months ended
September 30, 2020
  Three months ended
September 30, 2019
    Total   Common Stock   Class C Common
Stock
  Total   Common Stock   Class C Common
Stock
Basic                        
Numerator: 
Net income available to common stockholders
  $ 2,508     $ 2,355     $ 39     $ 3,299     $ 3,097     $ 51  
Denominator:                                                
Weighted average shares outstanding     6,447       6,447       383       6,432       6,432       383  
Basic income per common share   $ 0.39     $ 0.37     $ 0.10     $ 0.51     $ 0.48     $ 0.13  
Diluted                                                
Denominator:
Weighted average shares outstanding
            6,447       383               6,432       383  
Convertible Class C Stock             128       —                 128       —    
Total Denominator for diluted earnings per share             6,575       383               6,560       383  
Diluted income per common share           $ 0.36     $ 0.10             $ 0.47     $ 0.13  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)
3 Months Ended
Sep. 30, 2020
Receivables [Abstract]  
Summary of Allowance For Doubtful Accounts

Receivables, net is comprised of the following at September 30, 2020, and June 30, 2020:

 

    September 30, 2020  
    Gross Receivable     Allowance for doubtful accounts     Net  
Accounts receivable   $ 4,706     $ 515     $ 4,191  
Accounts receivable - related party   $ 102           $ 102  
Medical receivable   $ 16,293     $     $ 16,293  
Management and other fees receivable   $ 41,844     $ 12,833     $ 29,011  
Management and other fees receivable from related medical practices (“PC’s”)   $ 10,782     $ 3,780     $ 7,002  

 

    June 30, 2020  
    Gross Receivable     Allowance for doubtful accounts     Net  
Accounts receivable   $ 4,828     $ 515     $ 4,313  
Accounts receivable - related party   $ 6           $ 6  
Notes receivable   $ 16,172     $     $ 16,172  
Medical receivable   $ 16,172     $     $ 16,172  
Management and other fees receivable   $ 38,501     $ 11,063     $ 27,438  
Management and other fees receivable from related medical practices (“PC’s”)   $ 10,218     $ 3,322     $ 6,896  
Receivables - Non Current - net

Future revenue to be recognized over the following four years at September 30, 2020 are as follows:

 

2022   $ 879  
2023     827  
2024     827  
2025     228  
Total   $ 2,761  
Patient fee revenue - net

The Company’s patient fee revenue, net of contractual allowances and discounts for the three months ended September 30, 2020 and 2019 are summarized in the following table.

 

    For the Three Months Ended
September 30,
 
    2020     2019  
Commercial Insurance/ Managed Care   $ 946     $ 1,354  
Medicare/Medicaid     197       266  
Workers’ Compensation/Personal Injury     3,387       4,294  
Other     561       131  
Patient Fee Revenue, net of contractual allowances and discounts   $ 5,091     $ 6,045  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 4 - OPERATING & FINANCING LEASES (Tables)
3 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Lease, Liability, Maturity

A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of September 30, 2020 is as follows:

 

Year Ending
September 30,
  Operating Lease
Payments
    Financing Lease Payments  
2021   $ 5,045     $ 122  
2022     4,847       244  
2023     4,698       244  
2024     4,485       244  
2025     4,390       244  
Thereafter     18,545       408  
Present value discount     (9,331 )     (169 )
Total lease liability   $ 32,679     $ 1,337  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 5 - INVENTORIES (Tables)
3 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Inventories

Inventories included in the accompanying condensed consolidated balance sheets consist of the following:

 

   

September 30,

2020

 

June 30,

2020

Purchased parts, components and supplies   $ 1,537     $ 1,544  
Work-in-process     161       105  
TOTAL INVENTORIES   $ 1,698     $ 1,649  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables)
3 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Information relating to uncompleted contracts

Information relating to uncompleted contracts is as follows:

 

    September 30,
2020
    June 30,
 2020
 
Costs incurred on uncompleted contracts   $ 448     $ 448  
Estimated earnings     309       309  
Subtotal     757       757  
Less: Billings to date     604       604  
Total Costs and estimated earnings in excess of billings on uncompleted contracts   $ 153     $ 153  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 7 - OTHER INTANGIBLE ASSETS (Tables)
3 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Other intangible assets - net

Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:

 

    September 30,
2020
    June 30,
2020
 
Capitalized software development costs   $ 7,005     $ 7,005  
Patents and copyrights     5,101       5,082  
Non-compete     4,100       4,100  
Customer relationships     3,800       3,800  
Gross Other intangible assets     20,006       19,987  
Less: Accumulated amortization     15,970       15,878  
Other Intangible Assets   $ 4,036     $ 4,109  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 8 - OTHER CURRENT LIABILITIES (Tables)
3 Months Ended
Sep. 30, 2020
Other Liabilities, Current [Abstract]  
Other current liabilities

Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:

 

    September 30,
2020
    June 30,
2020
 
Accrued salaries, commissions and payroll taxes   $ 4,755     $ 4,492  
Litigation accruals     115       443  
Sales tax payable     1,362       1,353  
Legal and other professional fees     105       113  
Accounting fees     150       120  
Self-funded health insurance reserve     4       87  
Accrued interest and penalty     880       877  
Other     493       700  
Other Current Liabilities   $ 7,864     $ 8,185  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 9 - SEGMENT AND RELATED INFORMATION (Tables)
3 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Segment information

Summarized financial information concerning the Company’s reportable segments is shown in the following table:

 

    Medical
Equipment
    Management
of Diagnostic
Imaging
Centers
    Totals  
For the three months ended Sept. 30, 2020                  
Net revenues from external customers   $ 1,981     $ 18,998     $ 20,979  
Inter-segment net revenues   $ 219     $     $ 219  
(Loss) Income from operations   $ (561 )   $ 4,711     $ 4,150  
Depreciation and amortization   $ 67     $ 901     $ 968  
Capital expenditures   $ 20     $ 415     $ 435  
                         
 For the three months ended Sept. 30, 2019                        
Net revenues from external customers   $ 2,284     $ 19,463     $ 21,747  
Inter-segment net revenues   $ 219     $     $ 219  
(Loss) Income from operations   $ (736 )   $ 6,222     $ 5,486  
Depreciation and amortization   $ 91     $ 904     $ 995  
Capital expenditures   $ 1,601     $ 848     $ 2,449  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - Health Diagnostics Management LLC (HDM)
Jul. 01, 2015
The ownership interest of Imperial Management Services after reorganization of newly expanded HDM (percent). 24.20%
The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM (percent). 45.80%
The ownership interest of the original investors of HDM after reorganization of newly expanded HDM (percent). 30.00%
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Basic Numerator: Net income available to common stockholders $ 2,508 $ 3,299
Basic Denominator: Weighted average shares outstanding 6,447 6,432
Basic income per common share $ 0.39 $ 0.51
Shares included upon conversion of Class C Common to calculate a diluted EPS 128 128
Common Stock    
Basic Numerator: Net income available to common stockholders $ 2,355 $ 3,097
Basic Denominator: Weighted average shares outstanding 6,447 6,432
Basic income per common share $ 0.37 $ 0.48
Shares included upon conversion of Class C Common to calculate a diluted EPS 128 128
Total Denominator for diluted earnings per share 6,575 6,560
Diluted income per common share $ 0.36 $ 0.47
Class C Common Stock    
Basic Numerator: Net income available to common stockholders $ 39 $ 51
Basic Denominator: Weighted average shares outstanding 383 383
Basic income per common share $ 0.10 $ 0.13
Shares included upon conversion of Class C Common to calculate a diluted EPS
Total Denominator for diluted earnings per share 383 383
Diluted income per common share $ 0.10 $ 0.13
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares
shares in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Accounting Policies [Abstract]    
Shares included upon conversion of Class C Common to calculate a diluted EPS. 128 128
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Jun. 30, 2020
Accounts receivable $ 4,191 $ 4,313
Accounts receivable - Related party 102 6
Medical Receivables 16,293 16,172
Notes receivable   16,172
Management and other fees receivable 29,011 27,438
Management and other fees receivable from related medical practices ("PC's") 7,002 6,896
Gross Receivable    
Accounts receivable 4,706 4,828
Accounts receivable - Related party 102 6
Medical Receivables 16,293 16,172
Notes receivable   16,172
Management and other fees receivable 41,844 38,501
Management and other fees receivable from related medical practices ("PC's") 10,782 10,218
Allowance for Doubtful Accounts    
Accounts receivable 515 515
Accounts receivable - Related party 0 0
Medical Receivables 0 0
Notes receivable   0
Management and other fees receivable 12,833 11,063
Management and other fees receivable from related medical practices ("PC's") $ 3,780 $ 3,322
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE & MANAGEMENT & OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Receivables, Long-term Contracts or Programs [Abstract]  
2022 $ 879
2023 827
2024 827
2025 228
Total $ 2,761
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Patient fee revenue, net of contractual allowances and discounts $ 5,091 $ 6,045
Commercial Insurance / Managed Care    
Patient fee revenue, net of contractual allowances and discounts 946 1,354
Medicare/Medicaid    
Patient fee revenue, net of contractual allowances and discounts 197 266
Workers Compensation/Personal Injury    
Patient fee revenue, net of contractual allowances and discounts 3,387 4,294
Other    
Patient fee revenue, net of contractual allowances and discounts $ 561 $ 131
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative)
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Note 3 - Accounts Receivable Medical Receivable And Management And Other Fees Receivable -    
Percentage of PC's net revenue derived from no-fault and personal injury protection claims 66.00% 67.00%
Percentage of consolidated net revenue from management fees charged to related party medical practices 12.80% 11.00%
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 4 - OPERATING & FINANCING LEASES (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Operating Lease  
2021 $ 5,045
2022 4,847
2023 4,698
2024 4,485
2025 4,390
Thereafter 18,545
Present Value discount (9,331)
Total lease liability 32,679
Financing Lease  
2021 122
2022 244
2023 244
2024 244
2025 244
Thereafter 408
Present Value discount, Financing Lease (169)
Total lease liability $ 1,337
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 4 - OPERATING & FINANCING LEASES (Details Narrative)
3 Months Ended
Sep. 30, 2020
USD ($)
Leases [Abstract]  
Receivable from landlord for tenant improvements $ 202,268,000
Operating lease payments $ 33,300,000
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 5 - INVENTORIES (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Jun. 30, 2020
Inventory Disclosure [Abstract]    
Purchased parts, components and supplies $ 1,537 $ 1,544
Work-in-process 161 105
Total inventories $ 1,698 $ 1,649
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Jun. 30, 2020
Notes to Financial Statements    
Costs incurred on uncompleted contracts $ 448 $ 448
Estimated earnings 309 309
Costs and estimated earnings on uncompleted contracts 757 757
Less: Billings to date 604 604
Total costs and estimated earnings in excess of billings on uncompleted contracts $ 153 $ 153
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 7 - OTHER INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Jun. 30, 2020
Gross other intangible assets $ 20,006 $ 19,987
Less: Accumulated amortization 15,970 15,878
Other intangible assets-net 4,036 4,109
Capitalized software development costs    
Gross other intangible assets 7,005 7,005
Patents and copyrights    
Gross other intangible assets 5,101 5,082
Non-compete    
Gross other intangible assets 4,100 4,100
Customer relationships    
Gross other intangible assets $ 3,800 $ 3,800
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 7 - OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Patents and copyrights    
Amortization of intangible assets $ 45 $ 47
Non-compete    
Amortization of intangible assets 0 146
Customer relationships    
Amortization of intangible assets $ 48 $ 48
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 8 - OTHER CURRENT LIABILITIES (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Jun. 30, 2020
Other Liabilities, Current [Abstract]    
Accrued salaries, commissions and payroll taxes $ 4,755 $ 4,492
Litigation accruals 115 443
Sales tax payable 1,362 1,353
Legal and other professional fees 105 113
Accounting fees 150 120
Self-funded health insurance reserve 4 87
Accrued interest and penalty 880 877
Other 493 700
Other current liabilities $ 7,864 $ 8,185
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 9 - SEGMENT AND RELATED INFORMATION - Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Net revenues from external customers $ 20,979 $ 21,747
Inter-segment net revenues 219 219
(Loss) Income from operations 4,150 5,486
Depreciation and amortization 968 995
Capital expenditures 435 2,449
Medical Equipment    
Net revenues from external customers 1,981 2,284
Inter-segment net revenues 219 219
(Loss) Income from operations (561) (736)
Depreciation and amortization 67 91
Capital expenditures 20 1,601
Management Of Diagnostic Imaging Centers    
Net revenues from external customers 18,998 19,463
Inter-segment net revenues
(Loss) Income from operations 4,711 6,222
Depreciation and amortization 901 904
Capital expenditures $ 415 $ 848
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION ($) (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]    
Interest paid $ 19 $ 8
Income taxes paid $ 145 $ 228
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]    
Recorded tax obligations $ 1,362  
Tax interest and penalties 835  
Maximum limit for individual claims under stop-loss umbrella policy for health insurance 110  
Self-funded health insurance reserve $ 4 $ 87
Litigation settelement description In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company’s insurance in September 2020. The Company paid the remaining balance of $315 in September 2020.  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.20.2
NOTE 12 - INCOME TAXES (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Income Tax Disclosure [Abstract]    
Income tax expense $ 849 $ 1,107
Income tax component - current 0  
Income tax component - deferred 849  
Deferred tax assets 17,961  
Deferred tax liability 234  
Net operating loss (NOL) carryforwards available to offset future taxable income $ 49,925  
Reimbursement of alternative minimum tax credits description Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.  
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 87 311 1 false 23 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://fonar.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://fonar.com/role/BalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Sheet http://fonar.com/role/StatementsOfIncome CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) Sheet http://fonar.com/role/CondensedConsolidatedStatementsOfChangesInEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://fonar.com/role/StatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 00000007 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Sheet http://fonar.com/role/Note1-DescriptionOfBusinessAndBasisOfPresentation NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Notes 9 false false R10.htm 00000010 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES Sheet http://fonar.com/role/Note4-OperatingFinancingLeases NOTE 4 - OPERATING & FINANCING LEASES Notes 10 false false R11.htm 00000011 - Disclosure - NOTE 5 - INVENTORIES Sheet http://fonar.com/role/Note5-Inventories NOTE 5 - INVENTORIES Notes 11 false false R12.htm 00000012 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS Sheet http://fonar.com/role/Note6-CostsAndEstimatedEarningsOnUncompletedContracts NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS Notes 12 false false R13.htm 00000013 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS Sheet http://fonar.com/role/Note7-OtherIntangibleAssets NOTE 7 - OTHER INTANGIBLE ASSETS Notes 13 false false R14.htm 00000014 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES Sheet http://fonar.com/role/Note8-OtherCurrentLiabilities NOTE 8 - OTHER CURRENT LIABILITIES Notes 14 false false R15.htm 00000015 - Disclosure - NOTE 9 - SEGMENT AND RELATED INFORMATION Sheet http://fonar.com/role/Note9-SegmentAndRelatedInformation NOTE 9 - SEGMENT AND RELATED INFORMATION Notes 15 false false R16.htm 00000016 - Disclosure - NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION Sheet http://fonar.com/role/Note10-SupplementalCashFlowInformation NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION Notes 16 false false R17.htm 00000017 - Disclosure - NOTE 11 - COMMITMENTS AND CONTINGENCIES Sheet http://fonar.com/role/Note11-CommitmentsAndContingencies NOTE 11 - COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 00000018 - Disclosure - NOTE 12 - INCOME TAXES Sheet http://fonar.com/role/Note12-IncomeTaxes NOTE 12 - INCOME TAXES Notes 18 false false R19.htm 00000019 - Disclosure - NOTE 13 - SUBSEQUENT EVENTS Sheet http://fonar.com/role/Note13-SubsequentEvents NOTE 13 - SUBSEQUENT EVENTS Notes 19 false false R20.htm 00000020 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 00000021 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://fonar.com/role/Note2-SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables) Tables http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable 22 false false R23.htm 00000023 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Tables) Sheet http://fonar.com/role/Note4-OperatingFinancingLeasesTables NOTE 4 - OPERATING & FINANCING LEASES (Tables) Tables http://fonar.com/role/Note4-OperatingFinancingLeases 23 false false R24.htm 00000024 - Disclosure - NOTE 5 - INVENTORIES (Tables) Sheet http://fonar.com/role/Note5-InventoriesTables NOTE 5 - INVENTORIES (Tables) Tables http://fonar.com/role/Note5-Inventories 24 false false R25.htm 00000025 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables) Sheet http://fonar.com/role/Note6-CostsAndEstimatedEarningsOnUncompletedContractsTables NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables) Tables http://fonar.com/role/Note6-CostsAndEstimatedEarningsOnUncompletedContracts 25 false false R26.htm 00000026 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Tables) Sheet http://fonar.com/role/Note7-OtherIntangibleAssetsTables NOTE 7 - OTHER INTANGIBLE ASSETS (Tables) Tables http://fonar.com/role/Note7-OtherIntangibleAssets 26 false false R27.htm 00000027 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES (Tables) Sheet http://fonar.com/role/Note8-OtherCurrentLiabilitiesTables NOTE 8 - OTHER CURRENT LIABILITIES (Tables) Tables http://fonar.com/role/Note8-OtherCurrentLiabilities 27 false false R28.htm 00000028 - Disclosure - NOTE 9 - SEGMENT AND RELATED INFORMATION (Tables) Sheet http://fonar.com/role/Note9-SegmentAndRelatedInformationTables NOTE 9 - SEGMENT AND RELATED INFORMATION (Tables) Tables http://fonar.com/role/Note9-SegmentAndRelatedInformation 28 false false R29.htm 00000029 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Sheet http://fonar.com/role/Note1-DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Details http://fonar.com/role/Note1-DescriptionOfBusinessAndBasisOfPresentation 29 false false R30.htm 00000030 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPolicies-EarningsPerShareDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) Details 30 false false R31.htm 00000031 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetailsNarrative NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://fonar.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net (Details) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-ReceivablesNetDetails NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net (Details) Details http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables 32 false false R33.htm 00000033 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE & MANAGEMENT & OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableManagementOtherFeesReceivable-LongTermAccountsReceivableDetails NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE & MANAGEMENT & OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) Details 33 false false R34.htm 00000034 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue (Details) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-PatientFeesRevenueDetails NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue (Details) Details 34 false false R35.htm 00000035 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-DetailsNarrative NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative) Details http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables 35 false false R36.htm 00000036 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Details) Sheet http://fonar.com/role/Note4-OperatingFinancingLeasesDetails NOTE 4 - OPERATING & FINANCING LEASES (Details) Details http://fonar.com/role/Note4-OperatingFinancingLeasesTables 36 false false R37.htm 00000037 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Details Narrative) Sheet http://fonar.com/role/Note4-OperatingFinancingLeasesDetailsNarrative NOTE 4 - OPERATING & FINANCING LEASES (Details Narrative) Details http://fonar.com/role/Note4-OperatingFinancingLeasesTables 37 false false R38.htm 00000038 - Disclosure - NOTE 5 - INVENTORIES (Details) Sheet http://fonar.com/role/Note4-InventoriesDetails NOTE 5 - INVENTORIES (Details) Details http://fonar.com/role/Note5-InventoriesTables 38 false false R39.htm 00000039 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts (Details) Sheet http://fonar.com/role/Note6-CostsAndEstimatedEarningsOnUncompletedContracts-InformationRelatingToUncompletedContractsDetails NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts (Details) Details 39 false false R40.htm 00000040 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Details) Sheet http://fonar.com/role/Note7-OtherIntangibleAssetsDetails NOTE 7 - OTHER INTANGIBLE ASSETS (Details) Details http://fonar.com/role/Note7-OtherIntangibleAssetsTables 40 false false R41.htm 00000041 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Details Narrative) Sheet http://fonar.com/role/Note7-OtherIntangibleAssetsDetailsNarrative NOTE 7 - OTHER INTANGIBLE ASSETS (Details Narrative) Details http://fonar.com/role/Note7-OtherIntangibleAssetsTables 41 false false R42.htm 00000042 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES (Details) Sheet http://fonar.com/role/Note8-OtherCurrentLiabilitiesDetails NOTE 8 - OTHER CURRENT LIABILITIES (Details) Details http://fonar.com/role/Note8-OtherCurrentLiabilitiesTables 42 false false R43.htm 00000043 - Disclosure - NOTE 9 - SEGMENT AND RELATED INFORMATION - Segment Information (Details) Sheet http://fonar.com/role/Note9-SegmentAndRelatedInformation-SegmentInformationDetails NOTE 9 - SEGMENT AND RELATED INFORMATION - Segment Information (Details) Details 43 false false R44.htm 00000044 - Disclosure - NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION ($) (Details Narrative) Sheet http://fonar.com/role/Note10-SupplementalCashFlowInformationDetailsNarrative NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION ($) (Details Narrative) Details http://fonar.com/role/Note10-SupplementalCashFlowInformation 44 false false R45.htm 00000045 - Disclosure - NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://fonar.com/role/Note11-CommitmentsAndContingenciesDetailsNarrative NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://fonar.com/role/Note11-CommitmentsAndContingencies 45 false false R46.htm 00000046 - Disclosure - NOTE 12 - INCOME TAXES (Details Narrative) Sheet http://fonar.com/role/Note12-IncomeTaxesDetailsNarrative NOTE 12 - INCOME TAXES (Details Narrative) Details http://fonar.com/role/Note12-IncomeTaxes 46 false false All Reports Book All Reports fonr-20200930.xml fonr-20200930.xsd fonr-20200930_cal.xml fonr-20200930_def.xml fonr-20200930_lab.xml fonr-20200930_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 62 0000355019-20-000054-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000355019-20-000054-xbrl.zip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end